Cohort,Treatment,Biomarkers,Gene,Event,Association,Measurement,Evidence,Protein,Function,Database,Citations
Bladder Urothelial,Anti-PD-1,PD-L1,CD274,"Amplification, Expression",Response,"IHC, RNA-seq",High,Immune checkpoint ligand,Inhibits T-cell activation; high expression linked to better response,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC10486227/, https://pubmed.ncbi.nlm.nih.gov/33141317/, https://jitc.bmj.com/content/5/1/94, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2815767, https://einsteinmed.edu/uploadedFiles/Zang/UrologicOncology2017.pdf"
Bladder Urothelial,Anti-PD-1,TMB (Tumor Mutational Burden),Multiple,Mutation burden,Response,"WES, NGS",High,N/A (genomic feature),"High TMB increases neoantigen load, enhancing immune response","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC10486227/, https://jitc.bmj.com/content/5/1/94"
Bladder Urothelial,Immunotherapy,MSI (Microsatellite Instability),"MLH1, MSH2, MSH6, PMS2","Mutation, Deletion",Response,"PCR, NGS",High,DNA repair enzymes,Defective mismatch repair increases immunogenicity,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC10486227/, https://jitc.bmj.com/content/5/1/94"
Bladder Urothelial,Immunotherapy,CD8+ T-cell infiltration,N/A,N/A,Response,"IHC, Flow cytometry",High,Immune cell marker,High infiltration correlates with better ICI response,"TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC10486227/, https://jitc.bmj.com/content/5/1/94"
Breast ER+/HER-,Aromatase inhibitor,ER (Estrogen Receptor),ESR1,Expression,Response,"IHC, RNA-seq",High,Nuclear receptor,Mediates estrogen signaling; required for AI efficacy,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC6125140/
Breast ER+/HER-,Aromatase inhibitor,PR (Progesterone Receptor),PGR,Expression,Response,"IHC, RNA-seq",High,Nuclear receptor,Indicates functional ER pathway; low PR linked to poor response,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Aromatase inhibitor,HER2,ERBB2,Amplification,Non-response,"IHC, FISH, PCR",High,Receptor tyrosine kinase,HER2+ tumors less responsive to AIs,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6125140/
Breast ER+/HER-,Aromatase inhibitor,ESR1 Mutation,ESR1,Mutation,Non-response,"NGS, PCR",High,Nuclear receptor,Mutations confer resistance to AIs,"COSMIC, TCGA",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Aromatase inhibitor,PIK3CA Mutation,PIK3CA,Mutation,Non-response,"NGS, PCR",High,Enzyme (kinase),"Activates PI3K pathway, leading to endocrine resistance","COSMIC, TCGA",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Chemotherapy,Estrogen Receptor (ER),ESR1,Expression,Response,"IHC, RNA-seq",High,Nuclear receptor,"Mediates estrogen signaling, drives tumor growth, predicts endocrine therapy response","TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10378988/, https://arupconsult.com/content/breast-cancer"
Breast ER+/HER-,Chemotherapy,Progesterone Receptor (PR),PGR,Expression,Response,"IHC, RNA-seq",High,Nuclear receptor,"Modulates ER activity, associated with favorable outcome in ER+ tumors","TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10378988/, https://arupconsult.com/content/breast-cancer"
Breast ER+/HER-,Hormonal therapy,Estrogen Receptor,ESR1,"Expression, Mutation",Response/Non-response,"IHC, RNA-seq, Somatic Mutation",High,Nuclear receptor,Direct target of hormonal therapy; mutations can confer resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6125140/
Breast ER+/HER-,Hormonal therapy,Progesterone Receptor,PGR,Expression,Response,"IHC, RNA-seq",High,Nuclear receptor,Indicates functional ER pathway; higher levels predict better response,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC6125140/
Breast ER+/HER-,Hormonal therapy,HER2,ERBB2,Amplification,Non-response,"IHC, FISH",High,Receptor tyrosine kinase,HER2 amplification predicts poor response to hormonal therapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6125140/
Breast ER+/HER-,Hormonal therapy,PIK3CA,PIK3CA,Mutation,Non-response,"NGS, PCR",High,Kinase (enzyme),"Mutations activate PI3K pathway, leading to resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Hormonal therapy,Oncotype DX RS,Multi-gene,Expression profile,Response/Non-response,RT-PCR (21-gene panel),High,Multi-gene signature,Low RS predicts good response; high RS predicts poor response,"GEO, TCGA",https://pmc.ncbi.nlm.nih.gov/articles/PMC11564209/
Breast ER+/HER-,Hormonal therapy,Estrogen Receptor,ESR1,"Expression, Mutation",Response,"IHC, RNA-seq, PCR, Mutational",High,Nuclear receptor,Direct target of hormonal therapy; presence predicts response,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC6125140/, https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/"
Breast ER+/HER-,Hormonal therapy,Progesterone Receptor,PGR,Expression,Response,"IHC, RNA-seq",High,Nuclear receptor,Indicates functional ER pathway; higher levels predict better response,"TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC6125140/, https://cco.amegroups.org/article/view/45393/html"
Breast ER+/HER-,Hormonal therapy,HER2,ERBB2,Amplification,Non-response,"IHC, FISH, PCR",High,Receptor tyrosine kinase,HER2 amplification predicts poor response to hormonal therapy,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC6125140/, https://pmc.ncbi.nlm.nih.gov/articles/PMC11564209/"
Breast ER+/HER-,Hormonal therapy,PIK3CA,PIK3CA,Mutation,Non-response,"Sequencing, PCR",High,Kinase (PI3K pathway),Mutations linked to resistance to endocrine therapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Hormonal therapy,TP53,TP53,Mutation,Non-response,"Sequencing, PCR",High,Tumor suppressor,Mutations linked to poor prognosis and resistance,"TCGA, COSMIC",https://www.jcancer.org/v07p1281.htm
Breast ER+/HER-,Hormonal therapy,Oncotype DX RS,Multi-gene,Expression profile,Response/Non-resp,RT-PCR (21-gene panel),High,Multi-gene signature,"Low RS predicts response, high RS predicts non-response","GEO, TCGA","https://cco.amegroups.org/article/view/45393/html, https://pmc.ncbi.nlm.nih.gov/articles/PMC11564209/"
Breast ER+/HER-,Pyrimidine (ant)agonist,TYMS,TYMS,"Amplification, Mutation",Non-response,"RNA-seq, PCR, IHC",High,Enzyme (Thymidylate synthase),Catalyzes dTMP synthesis; overexpression confers resistance to 5-FU/capecitabine,"TCGA, COSMIC",https://research.rug.nl/files/2914175/thesis.pdf
Breast ER+/HER-,Pyrimidine (ant)agonist,DPYD,DPYD,"Mutation, Deletion",Non-response,"PCR, Somatic Mutation",High,Enzyme (Dihydropyrimidine dehydrogenase),"Catabolizes 5-FU; loss-of-function increases toxicity, alters response","TCGA, COSMIC",https://research.rug.nl/files/2914175/thesis.pdf
Breast Triple Negative,Chemotherapy,BRCA1,BRCA1,Mutation,Response,"Somatic Mutations, PCR",High,DNA repair enzyme,"Deficiency increases sensitivity to DNA-damaging agents (e.g., platinum)","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7369987/
Breast Triple Negative,Chemotherapy,BRCA2,BRCA2,Mutation,Response,"Somatic Mutations, PCR",High,DNA repair enzyme,"Similar to BRCA1, loss increases chemo sensitivity","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7369987/
Breast Triple Negative,Chemotherapy,TP53,TP53,Mutation,Non-response,"Somatic Mutations, PCR",High,Tumor suppressor,Mutations linked to chemoresistance and poor prognosis,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC4675910/
Breast Triple Negative,Chemotherapy,PD-L1,CD274,Amplification,Response,"IHC, RNA-seq",High,Immune checkpoint,High expression predicts better response to chemo-immunotherapy,"TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC7369987/, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.779786/full"
Breast Triple Negative,Chemotherapy,TILs,N/A,N/A,Response,"IHC, Histopathology",High,Immune cell marker,High levels predict better chemo response,"TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC7369987/, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.779786/full"
Colon,Chemotherapy,KRAS,KRAS,Mutation,Non-response,"Somatic mutation (PCR, NGS)",High,GTPase (enzyme),"Activates downstream signaling, confers resistance to anti-EGFR therapy","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6288499/
Colon,Chemotherapy,BRAF,BRAF,Mutation,Non-response,"Somatic mutation (PCR, NGS)",High,Serine/threonine kinase,"Drives MAPK pathway, predicts poor prognosis and anti-EGFR resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6288499/
Colon,Chemotherapy,HER2,ERBB2,Amplification,Non-response,"IHC, FISH, NGS",High,Receptor tyrosine kinase,"Bypasses EGFR blockade, confers resistance to anti-EGFR therapy","TCGA, COSMIC",https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.1062423/full
Colon,Chemotherapy,MMR status,MLH1/MSH2/etc,Deletion/Mutation,Response,"IHC, PCR, NGS",High,DNA repair enzyme,"Deficient MMR (dMMR) predicts poor response to 5-FU, but better immunotherapy","TCGA, COSMIC",https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,MSI status,Multiple,Genomic instability,Response,"PCR, NGS",High,N/A,"High MSI predicts poor response to 5-FU, better immunotherapy response","TCGA, COSMIC",https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,MSI (Microsatellite Instability),"MLH1, MSH2, MSH6, PMS2","Mutation, Deletion","Response (better prognosis, less benefit from 5-FU)","PCR, IHC, NGS",High,DNA repair enzymes,"Defective mismatch repair leads to high mutation rate, affects chemo sensitivity","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6288499/
Colon,Chemotherapy,KRAS mutation,KRAS,Mutation,Non-response,"PCR, NGS",High,GTPase (enzyme),"Activates downstream signaling, confers resistance to anti-EGFR therapy","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6288499/
Colon,Chemotherapy,BRAF V600E,BRAF,Mutation,Non-response,"PCR, NGS",High,Kinase (enzyme),"Activates MAPK pathway, poor prognosis, resistance to anti-EGFR therapy","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6288499/
Colon,Chemotherapy,MMR deficiency,"MLH1, MSH2, MSH6, PMS2","Mutation, Deletion","Response (to immunotherapy, less to chemo)","IHC, PCR, NGS",High,DNA repair enzymes,"Loss of mismatch repair, predicts response to immunotherapy, less to chemo","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6288499/
Gastroesophageal,Chemotherapy,MSI-H/dMMR,"MLH1, MSH2, MSH6, PMS2","Mutation, Deletion",Response,"PCR, IHC, NGS",High,DNA repair enzymes,"Deficient mismatch repair leads to high mutation burden, predicting response to immunotherapy[1][2].","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7530320/
Kidney,Multikinase inhibitor,VHL,VHL,Deletion/Mutation,Response,"Somatic mutation analysis (NGS, PCR)",High,E3 ubiquitin ligase,"Loss leads to HIF stabilization, promoting angiogenesis; VHL loss sensitizes to VEGF-TKIs","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC10419620/, https://ascopubs.org/doi/10.1200/EDBK_430734"
Kidney,Multikinase inhibitor,MET,MET,Amplification/Mutation,Non-response,"NGS, FISH, IHC",High,Receptor tyrosine kinase,"MET alterations linked to resistance to VEGF-TKIs, rationale for MET inhibitors","TCGA, COSMIC",https://ascopubs.org/doi/10.1200/EDBK_430734
Kidney,Targeted therapy,MET,MET,"Mutation, Amplification",Response,"NGS, FISH, IHC",High,Receptor tyrosine kinase,"Drives tumor growth in papillary RCC; predicts response to MET inhibitors (e.g., savolitinib)","TCGA, COSMIC",https://ascopubs.org/doi/10.1200/EDBK_430734
Kidney,Targeted therapy,VHL,VHL,"Mutation, Deletion",Response,"NGS, PCR",High,E3 ubiquitin ligase,"Loss leads to HIF stabilization, sensitivity to HIF2α inhibitors (e.g., belzutifan)","TCGA, COSMIC",https://ascopubs.org/doi/10.1200/EDBK_430734
Lung NSCLC,Anti-PD-1,TMB (Tumor Mutational Burden),Multiple,Mutation burden,Response,"Whole exome sequencing, NGS",High,N/A (genomic metric),"High TMB increases neoantigen load, enhancing immune response","TCGA, COSMIC","https://pubmed.ncbi.nlm.nih.gov/36822668/, https://www.cancernetwork.com/view/print-biomarkers-for-response-to-anti-pd-1-anti-pd-l1-immune-checkpoint-inhibitors-a-large-meta-analysis"
Lung NSCLC,Anti-PD-1,EGFR Mutation,EGFR,Mutation,Non-response,"PCR, NGS, Sanger sequencing",High,Receptor tyrosine kinase,EGFR mutations linked to resistance to anti-PD-1/PD-L1,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10351040/
Lung NSCLC,Anti-PD-1,ALK Rearrangement,ALK,Rearrangement,Non-response,"FISH, NGS, PCR",High,Receptor tyrosine kinase,ALK fusions associated with poor response to anti-PD-1/PD-L1,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10351040/
Lung NSCLC,Anti-PD-1,CD8+ TILs,N/A,Infiltration,Response,"IHC, Flow cytometry",High,Immune cell marker,High CD8+ TILs indicate active anti-tumor immunity,TCGA,"https://pmc.ncbi.nlm.nih.gov/articles/PMC10351040/, https://jitc.bmj.com/content/4/1/48"
Lung NSCLC,Chemotherapy,EGFR,EGFR,Mutation,Response,"PCR, NGS, IHC",High,Receptor tyrosine kinase,"EGFR mutations predict response to EGFR TKIs, but may affect chemo sensitivity","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC6025105/, https://www.frontiersin.org/journals/oncology-reviews/articles/10.3389/or.2024.1445826/full"
Lung NSCLC,Chemotherapy,ALK,ALK,Rearrangement,Response,"FISH, IHC, NGS",High,Receptor tyrosine kinase,"ALK rearrangement predicts response to ALK inhibitors, may affect chemo response","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC6025105/, https://www.frontiersin.org/journals/oncology-reviews/articles/10.3389/or.2024.1445826/full"
Lung NSCLC,Chemotherapy,ROS1,ROS1,Rearrangement,Response,"FISH, IHC, NGS",High,Receptor tyrosine kinase,"ROS1 rearrangement predicts response to ROS1 inhibitors, may affect chemo response","TCGA, COSMIC",https://www.frontiersin.org/journals/oncology-reviews/articles/10.3389/or.2024.1445826/full
Lung NSCLC,Chemotherapy,PD-L1,CD274,Expression,Response,IHC,High,Immune checkpoint,High PD-L1 expression predicts response to immunotherapy ± chemo,"TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC6025105/, https://www.frontiersin.org/journals/oncology-reviews/articles/10.3389/or.2024.1445826/full"
Lung NSCLC,Immunotherapy,Tumor Mutational Burden (TMB),Multiple,Somatic Mutations,Response,"NGS, WES",High,N/A (genomic signature),"High TMB increases neoantigen load, enhancing immune recognition","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC7471728/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10418476/"
Lung NSCLC,Immunotherapy,EGFR Mutation,EGFR,Mutation,Non-response,"PCR, NGS",High,Receptor tyrosine kinase,EGFR mutations linked to poor ICI response,"TCGA, COSMIC",https://pcm.amegroups.org/article/view/7603/html
Lung NSCLC,Immunotherapy,ALK Rearrangement,ALK,Rearrangement,Non-response,"FISH, NGS",High,Receptor tyrosine kinase,ALK fusions associated with poor ICI response,"TCGA, COSMIC",https://pcm.amegroups.org/article/view/7603/html
Lung NSCLC,Immunotherapy,ROS1 Rearrangement,ROS1,Rearrangement,Non-response,"FISH, NGS",High,Receptor tyrosine kinase,ROS1 fusions associated with poor ICI response,"TCGA, COSMIC",https://pcm.amegroups.org/article/view/7603/html
Ovary,Chemotherapy,BRCA2,BRCA2,Mutation,Response,"PCR, NGS, IHC",High,DNA repair enzyme,Similar to BRCA1; predicts better response to platinum chemotherapy,"TCGA, COSMIC",https://www.targetedonc.com/view/the-role-of-biomarker-testing-in-ovarian-cancer
Ovary,Chemotherapy,HRD Score,Multiple,Genomic instability,Response,"Genomic scar assay, NGS",High,N/A (composite),High HRD score predicts sensitivity to platinum and PARP inhibitors,TCGA,https://www.targetedonc.com/view/the-role-of-biomarker-testing-in-ovarian-cancer
Pan-Cancer,Alkaloid,p53,TP53,Mutation,Non-response,"Somatic Mutations, IHC",High,Tumor suppressor,"Loss of function impairs apoptosis, reducing response to alkaloids","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8716855/
Pan-Cancer,Alkaloid,BRCA1,BRCA1,Mutation,Response,"Somatic Mutations, PCR",High,DNA repair protein,Deficiency sensitizes cells to DNA-damaging alkaloids,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8716855/
Pan-Cancer,Alkylating,SLFN11,SLFN11,Expression,Response,"RNA-seq, IHC, promoter methylation",High,Enzyme-like protein,Promotes cell death in response to DNA damage; high expression predicts sensitivity to alkylating agents.,"TCGA, GEO","https://journals.plos.org/plosone/article/file?id=10.1371%2Fjournal.pone.0224267&type=printable, https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0224267"
Pan-Cancer,Alkylating,MGMT,MGMT,"Promoter methylation, mutation","Non-response (when active), Response (when methylated)","Methylation-specific PCR, IHC, sequencing",High,DNA repair enzyme,"Repairs alkylated DNA; active MGMT confers resistance, methylation predicts response.","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC9019174/
Pan-Cancer,Anti-AR,AR Amplification,AR,Amplification,Non-response,"DNA copy number (WES, FISH)",High,Nuclear receptor,Increased AR gene copies drive resistance by sustaining AR signaling despite therapy,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC8750084/, https://www.spandidos-publications.com/10.3892/wasj.2025.313, https://www.mdpi.com/2072-6694/13/22/5723"
Pan-Cancer,Anti-AR,AR-V7,AR,Splice Variant,Non-response,"RT-PCR, RNA-seq",High,Nuclear receptor,"Constitutively active AR variant, bypasses ligand blockade","GEO, TCGA","https://www.spandidos-publications.com/10.3892/wasj.2025.313, https://www.mdpi.com/2072-6694/13/22/5723"
Pan-Cancer,Anti-AR,TP53 Mutation,TP53,Mutation,Non-response,"WES, targeted sequencing",High,Tumor suppressor,"Disrupts cell cycle control, associated with poor response","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC5955785/, https://www.mdpi.com/2072-6694/13/22/5723"
Pan-Cancer,Anti-AR,PTEN Loss,PTEN,Deletion/Mutation,Non-response,"IHC, WES",High,Phosphatase,"Loss activates PI3K/AKT pathway, conferring resistance","TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/22/5723
Pan-Cancer,Anti-AR,PSA (KLK3),KLK3,Overexpression,Response,"Serum ELISA, IHC",High,Serine protease,Decrease in PSA indicates response to AR-targeted therapy,"TCGA, GEO",https://www.mdpi.com/2072-6694/13/22/5723
Pan-Cancer,Anti-CTLA-4,CTLA-4,CTLA4,Amplification,Response,"RNA-seq, IHC",High,Immune checkpoint,Inhibits T cell activation; target of therapy,"TCGA, TIMER",https://pmc.ncbi.nlm.nih.gov/articles/PMC11973099/
Pan-Cancer,Anti-CTLA-4,PD-1,PDCD1,Amplification,Non-response,"RNA-seq, IHC",High,Immune checkpoint,Marker of T cell exhaustion; high expression linked to immune evasion,"TCGA, TIMER",https://pmc.ncbi.nlm.nih.gov/articles/PMC11973099/
Pan-Cancer,Anti-CTLA-4,CD8+ Memory T Cells,CD8A,N/A,Response,"CyTOF, Flow cytometry",High,T cell marker,Presence indicates robust anti-tumor immunity,"GEO, TCGA","https://pmc.ncbi.nlm.nih.gov/articles/PMC5840795/, https://pubmed.ncbi.nlm.nih.gov/29510697/"
Pan-Cancer,Anti-CTLA-4,CD4+ Memory T Cells,CD4,N/A,Response,"CyTOF, Flow cytometry",High,T cell marker,Associated with effective immune response,"GEO, TCGA","https://pmc.ncbi.nlm.nih.gov/articles/PMC5840795/, https://pubmed.ncbi.nlm.nih.gov/29510697/"
Pan-Cancer,Anti-CTLA-4,Tumor Mutational Burden (TMB),Multiple,Mutation,Response,"WES, NGS",High,N/A (genomic feature),"High TMB increases neoantigen load, enhancing immune recognition","TCGA, COSMIC",https://jitc.bmj.com/content/8/Suppl_3/A46
Pan-Cancer,Anti-EGFR,BRAF V600E,BRAF,Mutation,Non-response,"Somatic mutation (NGS, PCR)",High,Kinase (enzyme),"Constitutive MAPK activation, reduces anti-EGFR efficacy","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC4974592/, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Anti-PD-1,T cell–inflamed GEP,Multiple,Expression,Response,"RNA-seq, gene expression profiling",High,N/A (Gene Signature),Reflects pre-existing immune activation in tumor microenvironment,"TCGA, GEO",https://www.science.org/doi/10.1126/science.aar3593
Pan-Cancer,Anti-PD-1,MMR Deficiency,"MLH1, MSH2, etc.","Mutation, Deletion",Response,"PCR, IHC, NGS",High,Enzyme,Defective mismatch repair increases neoantigen load,"TCGA, COSMIC",https://www.cancernetwork.com/view/print-biomarkers-for-response-to-anti-pd-1-anti-pd-l1-immune-checkpoint-inhibitors-a-large-meta-analysis
Pan-Cancer,Anti-PD-1,STK11/LKB1,STK11,"Mutation, Deletion",Non-response,"NGS, PCR",High,Kinase,"Loss impairs immune infiltration, linked to resistance","TCGA, COSMIC",https://www.cancernetwork.com/view/print-biomarkers-for-response-to-anti-pd-1-anti-pd-l1-immune-checkpoint-inhibitors-a-large-meta-analysis
Pan-Cancer,Anti-VEGF,VEGFA,VEGFA,"Amplification, Overexpression",Response/Non-response,"RNA-seq, IHC, ELISA",High,Growth factor,Central mediator of angiogenesis; target of anti-VEGF therapy,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC9667458/
Pan-Cancer,Anti-VEGF,VEGFR2,KDR,"Amplification, Mutation",Response/Non-response,"IHC, RNA-seq, PCR",High,Receptor tyrosine kinase,Main receptor for VEGFA; mediates angiogenic signaling,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC9667458/
Pan-Cancer,Aromatase inhibitor,TP53 Mutation,TP53,Mutation,Non-response,Somatic mutation analysis,High,Tumor suppressor,TP53 mutations linked to poor AI response and aggressive tumor phenotype,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10328947/
Pan-Cancer,Aromatase inhibitor,HER2,ERBB2,Amplification,Non-response,"IHC, FISH, Copy number",High,Receptor tyrosine kinase,"HER2 amplification drives growth independent of estrogen, reducing AI efficacy","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10328947/
Pan-Cancer,Aromatase inhibitor,Ki67,MKI67,Overexpression,Non-response,IHC,High,Proliferation marker,High proliferation index predicts poor response to AI,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10328947/
Pan-Cancer,Chemotherapy,TP53 Mutation,TP53,Mutation,Non-response,"NGS, PCR",High,Transcription factor,Tumor suppressor; mutations linked to resistance to DNA-damaging agents,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/
Pan-Cancer,Chemotherapy,BRCA1/2 Mutation,BRCA1/2,Mutation,Response,"NGS, PCR",High,DNA repair enzyme,Deficiency sensitizes to platinum-based chemo,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/
Pan-Cancer,Chemotherapy,MGMT Methylation,MGMT,Promoter methyl.,Response,Methylation-specific PCR,High,DNA repair enzyme,"Methylation silences gene, increases alkylating agent sensitivity","TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Chemotherapy,TP53,TP53,Mutation,Non-response,"NGS, PCR",High,Transcription factor,Tumor suppressor; mutations linked to resistance to DNA-damaging agents,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Chemotherapy,BRCA1/2,BRCA1/2,Mutation,Response,"NGS, PCR",High,DNA repair enzyme,HRD mutations sensitize to platinum-based chemo,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Chemotherapy,ERCC1,ERCC1,Overexpression,Non-response,"IHC, qPCR",High,DNA repair enzyme,High expression linked to platinum resistance,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Chemotherapy,MGMT,MGMT,Methylation,Response,Methylation-specific PCR,High,DNA repair enzyme,Promoter methylation predicts response to alkylating agents,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Chemotherapy,TP53,TP53,Mutation,Non-response,"Somatic mutation (NGS, PCR)",High,Transcription factor,Tumor suppressor; mutations linked to poor chemo response,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/
Pan-Cancer,Chemotherapy,BRCA1/2,BRCA1/2,Mutation,Response,Germline/somatic mutation (NGS),High,DNA repair enzyme,Deficiency sensitizes to platinum-based chemo,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/
Pan-Cancer,Chemotherapy,ERCC1,ERCC1,Overexpression,Non-response,"RNA-seq, IHC",High,DNA repair enzyme,High levels confer resistance to platinum chemo,"TCGA, GEO, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Chemotherapy,MGMT,MGMT,Methylation,Response,Methylation-specific PCR,High,DNA repair enzyme,Promoter methylation predicts response to alkylating agents,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Folinic acid,Thymidylate Synthase (TS),TYMS,"Amplification, Overexpression",Non-response,"IHC, RNA-seq, PCR",High,Enzyme,High TS expression reduces 5-FU/FA efficacy by increasing dTMP synthesis,"TCGA, COSMIC",https://www.oncotarget.com/article/27872/text/
Pan-Cancer,Folinic acid,Dihydropyrimidine Dehydrogenase (DPYD),DPYD,"Mutation, Deletion",Non-response,"PCR, NGS, Enzyme assay",High,Enzyme,"DPYD deficiency increases 5-FU toxicity, affecting FA-based therapy","TCGA, COSMIC",https://www.oncotarget.com/article/27872/text/
Pan-Cancer,Folinic acid,RAS (KRAS/NRAS),KRAS/NRAS,Mutation,Non-response,"PCR, NGS",High,GTPase,RAS mutations predict poor response to FA/5-FU + anti-EGFR therapy,"TCGA, COSMIC","https://pubmed.ncbi.nlm.nih.gov/37018649/, https://www.oncotarget.com/article/27872/text/"
Pan-Cancer,Folinic acid,BRAF,BRAF,Mutation,Non-response,"PCR, NGS",High,Kinase,BRAF V600E mutation linked to poor prognosis and reduced FA therapy response,"TCGA, COSMIC",https://pubmed.ncbi.nlm.nih.gov/37018649/
Pan-Cancer,Folinic acid,Consensus Molecular Subtype 2 (CMS2),Multiple,Transcriptomic profile,Response,"RNA-seq, Transcriptomics",High,Mixed,CMS2 subtype shows better response to FA/5-FU + panitumumab,TCGA,https://pubmed.ncbi.nlm.nih.gov/37018649/
Pan-Cancer,Folinic acid,Consensus Molecular Subtype 1 (CMS1),Multiple,Transcriptomic profile,Non-response,"RNA-seq, Transcriptomics",High,Mixed,CMS1 subtype shows poor response to FA/5-FU + panitumumab,TCGA,https://pubmed.ncbi.nlm.nih.gov/37018649/
Pan-Cancer,Folinic acid,Epidermal Growth Factor Receptor (EGFR),EGFR,"Amplification, Mutation",Response,"IHC, PCR, NGS",High,Receptor tyrosine kinase,EGFR wild-type status predicts benefit from FA/5-FU + anti-EGFR therapy,"TCGA, COSMIC","https://pubmed.ncbi.nlm.nih.gov/37018649/, https://www.oncotarget.com/article/27872/text/"
Pan-Cancer,Folinic acid,Microsatellite Instability (MSI),Multiple,Genomic instability,Response,"PCR, NGS, IHC",High,Genomic marker,MSI-high tumors show better response to FA/5-FU therapies,"TCGA, COSMIC",https://pubmed.ncbi.nlm.nih.gov/37018649/
Pan-Cancer,Hormonal therapy,HER2,ERBB2,Amplification,Non-response,"IHC, FISH, PCR",High,Receptor tyrosine kinase,Overexpression linked to endocrine resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,BRCA1,BRCA1,"Mutation, Deletion",Response,"NGS, PCR, Somatic mutation",High,DNA repair enzyme,Loss increases sensitivity to PARP inhibitors,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Hormonal therapy,BRCA2,BRCA2,"Mutation, Deletion",Response,"NGS, PCR, Somatic mutation",High,DNA repair enzyme,Loss increases sensitivity to PARP inhibitors,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Hormonal therapy,PIK3CA,PIK3CA,Mutation,Non-response,"NGS, PCR",High,Enzyme (kinase),Activating mutations drive resistance to hormonal therapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,TP53,TP53,Mutation,Non-response,"NGS, PCR",High,Tumor suppressor,Mutations associated with poor response,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,HER2,ERBB2,Amplification,Non-response,"IHC, FISH, PCR",High,Receptor tyrosine kinase,"HER2+ tumors less responsive to hormonal therapy, may require HER2-targeted tx","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,ESR1 Mutations,ESR1,Mutation,Non-response,"NGS, PCR",High,Nuclear receptor,Mutations confer resistance to endocrine therapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,PI3K Pathway,PIK3CA,Mutation,Non-response,"NGS, PCR",High,Kinase,Activating mutations linked to resistance to hormonal therapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Immunotherapy,PD-L1,CD274,"Amplification, Overexpression",Response,"IHC, RNA-seq",High,Immune checkpoint ligand,Inhibits T-cell activation; high expression predicts response to PD-1/PD-L1 blockade,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/
Pan-Cancer,Immunotherapy,TMB (Tumor Mutational Burden),Multiple,Somatic Mutations,Response,"WES, NGS",High,N/A (genomic feature),"High TMB increases neoantigen load, enhancing immunogenicity","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC9500013/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/"
Pan-Cancer,Immunotherapy,MSI-H/dMMR,"MLH1, MSH2, MSH6, PMS2","Mutation, Deletion",Response,"PCR, IHC, NGS",High,DNA repair enzymes,"Defective mismatch repair increases mutation load, improving ICI response","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC9500013/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/"
Pan-Cancer,Immunotherapy,B2M,B2M,"Mutation, Deletion",Non-response,"NGS, PCR",High,MHC class I component,"Loss impairs antigen presentation, leading to immune evasion","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/
Pan-Cancer,Immunotherapy,JAK1/JAK2,"JAK1, JAK2","Mutation, Deletion",Non-response,"NGS, PCR",High,Kinase,"Mutations disrupt IFN-γ signaling, reducing immune response","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/
Pan-Cancer,Immunotherapy,EGFR,EGFR,"Mutation, Amplification",Non-response,"NGS, PCR",High,Receptor tyrosine kinase,"EGFR mutations linked to poor ICI response, especially in NSCLC","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/
Pan-Cancer,Immunotherapy,HLA Class I,HLA-A/B/C,"Mutation, Deletion",Non-response,"NGS, PCR",High,Antigen-presenting molecule,Loss impairs immune recognition of tumor cells,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/
Pan-Cancer,Immunotherapy,CD8+ TILs,N/A,N/A,Response,"IHC, Flow cytometry",High,Immune cell marker,High infiltration predicts better ICI response,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/
Pan-Cancer,Multikinase inhibitor,PIK3CA (Hotspot),PIK3CA,Mutation,Response,"Somatic Mutation (PCR, NGS)",High,Kinase (enzyme),Activates PI3K pathway; predicts response to PI3K inhibitors,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Multikinase inhibitor,NTRK Fusion,NTRK1/2/3,Fusion,Response,"Fusion detection (NGS, FISH)",High,Kinase (enzyme),Drives oncogenesis; predicts response to TRK inhibitors,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Multikinase inhibitor,EGFR (Exon 19/21),EGFR,Mutation,Response,"Somatic Mutation (PCR, NGS)",High,Receptor tyrosine kinase,Activates EGFR pathway; predicts response to EGFR inhibitors,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Multikinase inhibitor,ALK Fusion,ALK,Fusion,Response,"Fusion detection (NGS, FISH)",High,Kinase (enzyme),Oncogenic driver; predicts response to ALK inhibitors,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Multikinase inhibitor,RET Fusion,RET,Fusion,Response,"Fusion detection (NGS, FISH)",High,Kinase (enzyme),Oncogenic driver; predicts response to RET inhibitors,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Multikinase inhibitor,HER2 Amplification,ERBB2,Amplification,Response,"Copy number (FISH, IHC)",High,Receptor tyrosine kinase,Promotes growth; predicts response to HER2-targeted therapies,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Multikinase inhibitor,KIT Mutation,KIT,Mutation,Response,"Somatic Mutation (PCR, NGS)",High,Receptor tyrosine kinase,Oncogenic driver; predicts response to KIT inhibitors,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Platinum,TP53,TP53,Mutation,Non-response,Somatic mutation sequencing,High,Tumor suppressor,"Mutations often confer resistance to DNA-damaging agents, including platinum","TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Platinum,ERCC1,ERCC1,Overexpression,Non-response,"RNA-seq, IHC",High,DNA repair enzyme,"High expression repairs platinum-induced DNA damage, leading to resistance","TCGA, GEO",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Platinum,BRCA1,BRCA1,"Mutation, Deletion",Response,"Somatic/germline mutation testing (NGS, PCR)",High,DNA repair enzyme,"Loss impairs homologous recombination, sensitizing to platinum agents","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC8928350/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10401074/, https://www.binasss.sa.cr/set21/46.pdf, https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full"
Pan-Cancer,Platinum,BRCA2,BRCA2,"Mutation, Deletion",Response,"Somatic/germline mutation testing (NGS, PCR)",High,DNA repair enzyme,"Loss impairs homologous recombination, sensitizing to platinum agents","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC8928350/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10401074/, https://www.binasss.sa.cr/set21/46.pdf, https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full"
Pan-Cancer,Platinum,ERCC1,ERCC1,"Deletion, Low expression",Non-response,"IHC, RNA-seq, qPCR",High,DNA repair enzyme,Nucleotide excision repair; high expression confers platinum resistance,"TCGA, GEO",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Pyrimidine (ant)agonist,EGFR,EGFR,"Mutation, Amplification",Non-response,"Somatic mutation, PCR",High,Receptor tyrosine kinase,"Activates MAPK pathway, upregulates pyrimidine synthesis, confers resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8194085/
Pan-Cancer,Targeted therapy,BRAF V600E mutation,BRAF,Mutation,Response,"PCR, NGS",High,Kinase,Activates MAPK pathway; predicts response to BRAF inhibitors,"TCGA, COSMIC",https://pubmed.ncbi.nlm.nih.gov/34373099/
Pan-Cancer,Targeted therapy,KRAS mutation,KRAS,Mutation,Non-response,"PCR, NGS",High,GTPase,Constitutive signaling; predicts resistance to EGFR inhibitors,"TCGA, COSMIC",https://pubmed.ncbi.nlm.nih.gov/34373099/
Pan-Cancer,Targeted therapy,HER2 amplification,ERBB2,Amplification,Response,"FISH, IHC, NGS",High,Receptor tyrosine kinase,Overexpression drives growth; predicts response to HER2-targeted therapy,"TCGA, COSMIC",https://pubmed.ncbi.nlm.nih.gov/34373099/
Pan-Cancer,Targeted therapy,NTRK fusion,NTRK1/2/3,Gene rearrangement,Response,"NGS, FISH",High,Receptor tyrosine kinase,Constitutive kinase activity; predicts response to TRK inhibitors,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Targeted therapy,ROS1 fusion,ROS1,Gene rearrangement,Response,"FISH, NGS",High,Receptor tyrosine kinase,Constitutive kinase activity; predicts response to ROS1 inhibitors,"TCGA, COSMIC",https://pubmed.ncbi.nlm.nih.gov/34373099/
Pan-Cancer,Targeted therapy,RET fusion,RET,Gene rearrangement,Response,"NGS, FISH",High,Receptor tyrosine kinase,Constitutive kinase activity; predicts response to RET inhibitors,"TCGA, COSMIC",https://pubmed.ncbi.nlm.nih.gov/34373099/
Pan-Cancer,Targeted therapy,BRCA1/2 mutation,BRCA1/2,Mutation,Response,"NGS, PCR",High,DNA repair enzyme,Homologous recombination deficiency; predicts response to PARP inhibitors,"TCGA, COSMIC",https://pubmed.ncbi.nlm.nih.gov/34373099/
Pan-Cancer,Targeted therapy,MSI-High,MLH1/MSH2/etc,Disruption,Response,"PCR, NGS, IHC",High,DNA mismatch repair,High mutation rate; predicts response to immune checkpoint inhibitors,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC9500013/, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Targeted therapy,TMB-High,Multiple,Mutation burden,Response,NGS,High,Various,High neoantigen load; predicts response to immunotherapy,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC9500013/, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Taxane,ABCB1 (MDR1),ABCB1,Amplification,Non-response,"PCR, IHC, RNA-seq",High,Transporter,Drug efflux pump; overexpression leads to taxane resistance,"TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/16/4055
Pan-Cancer,Taxane,TUBB3,TUBB3,Expression,Non-response,"IHC, RNA-seq",High,Structural protein,Beta-tubulin isotype; high expression linked to taxane resistance,"TCGA, GEO",https://www.mdpi.com/2072-6694/13/16/4055
Pan-Cancer,Taxane,BRCA1,BRCA1,Mutation,Response,"Somatic Mutation, PCR",High,DNA repair enzyme,Loss-of-function mutations sensitize to taxanes,"TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/16/4055
Pan-Cancer,Taxane,TP53,TP53,Mutation,Non-response,"Somatic Mutation, PCR",High,Tumor suppressor,Mutations linked to poor response to taxanes,"TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/16/4055
Pancreas PAAD,Chemotherapy,CA19-9,FUT3,Overexpression,Response,Serum ELISA,High,Glycoprotein,Tumor marker; decrease after chemo predicts response,"TCGA, GEO",https://tcr.amegroups.org/article/view/18840/14924
Pancreas PAAD,Chemotherapy,ctDNA (KRAS),KRAS,Mutation,Non-response,"Liquid biopsy, PCR, NGS",High,GTPase (enzyme),Persistent mutant ctDNA predicts poor response,"TCGA, COSMIC",https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full
Pancreas PAAD,Chemotherapy,hENT1,SLC29A1,Downregulation,Non-response,"IHC, RNA-seq",High,Nucleoside transporter,Low expression predicts gemcitabine resistance,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10293428/
Pancreas PAAD,Chemotherapy,BRCA1/2,BRCA1/2,Mutation,Response,Germline/somatic sequencing,High,DNA repair enzyme,Mutations predict platinum sensitivity,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10293428/
Pancreas PAAD,Folinic acid,CA 19-9,N/A,N/A,Response,Serum ELISA,High,Glycoprotein,Tumor marker for diagnosis and response assessment,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC6478006/
Pancreas PAAD,Folinic acid,GATA6,GATA6,Expression,Response,"RNA-seq, IHC",High,Transcription factor,"High expression linked to classical subtype, better response to 5-FU/FOLFIRINOX","TCGA, GEO",https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full
Pancreas PAAD,Folinic acid,KRAS Mutation,KRAS,Mutation,Non-response,"PCR, NGS",High,GTPase,"Oncogenic driver, associated with poor response to chemotherapy","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6478006/
Pancreas PAAD,Folinic acid,TP53 Mutation,TP53,Mutation,Non-response,"PCR, NGS",High,Tumor suppressor,Loss of function linked to chemoresistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6478006/
Prostate,Anti-AR,AR-V7,AR,Splice Variant,Non-response,"RT-PCR, RNA-seq, IHC",High,Nuclear receptor,Constitutively active AR variant; confers resistance to anti-AR therapies,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC9319825/
Prostate,Anti-AR,AR Amplification,AR,Amplification,Non-response,"FISH, NGS, qPCR",High,Nuclear receptor,"Increases AR signaling, driving resistance to AR-targeted agents","TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/22/5723
Prostate,Anti-AR,High AR Activity,AR,Overexpression,Response,Gene expression signature,High,Nuclear receptor,Predicts response to bipolar androgen therapy (BAT),"TCGA, GEO",https://www.jci.org/articles/view/165357
Prostate,Anti-AR,PTEN Loss,PTEN,Deletion/Mutation,Non-response,"IHC, FISH, NGS",High,Phosphatase,"Loss activates PI3K/AKT pathway, reducing AR dependency","TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/22/5723
Prostate,Anti-AR,DNA Repair Defects,"BRCA2, ATM",Mutation/Deletion,Non-response,"NGS, HRD panel",High,DNA repair enzymes,Defective repair linked to poor response to AR-targeted agents,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC9319825/
Prostate,Anti-AR,PSA (KLK3),KLK3,Overexpression,Response,Serum ELISA,High,Serine protease,Decline in PSA indicates response to AR-targeted therapy,"TCGA, GEO",https://www.jci.org/articles/view/165357
Prostate,Chemotherapy,PSA,KLK3,Amplification,Response,"Immunoassay (IHC, ELISA)",High,Enzyme (serine protease),Marker of tumor burden; decline indicates response to therapy,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10649216/
Prostate,Chemotherapy,AR-V7,AR,Splice Variant,Non-response,"RT-PCR, RNA-seq",High,Nuclear receptor,Predicts resistance to AR-targeted therapies and some chemotherapies,"COSMIC, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC5524249/, https://www.mdpi.com/2072-6694/13/22/5723"
Prostate,Chemotherapy,BRCA2,BRCA2,Deletion/Mutation,Response,"NGS, PCR",High,DNA repair enzyme,"Loss sensitizes to PARP inhibitors, platinum-based chemotherapy","COSMIC, TCGA","https://pmc.ncbi.nlm.nih.gov/articles/PMC5524249/, https://www.mdpi.com/2072-6694/13/22/5723"
Prostate,Chemotherapy,TP53,TP53,Mutation,Non-response,"NGS, IHC",High,Tumor suppressor,Mutations linked to poor response to chemotherapy,"COSMIC, TCGA",https://www.mdpi.com/2072-6694/13/22/5723
Prostate,Chemotherapy,PTEN,PTEN,Deletion/Mutation,Non-response,"IHC, NGS",High,Phosphatase,Loss associated with aggressive disease and poor chemo response,"COSMIC, TCGA",https://www.mdpi.com/2072-6694/13/22/5723
Prostate,Chemotherapy,PHI (Prostate Health Index),KLK2/KLK3,Composite (PSA isoforms),Response,Immunoassay (ELISA),High,Enzyme panel,Combines PSA isoforms for improved risk stratification and therapy monitoring,"TCGA, GEO",https://tau.amegroups.org/article/view/69981/html
Prostate,Hormonal therapy,Androgen Receptor Amplification (ARamp),AR,Amplification,Non-response,"Somatic mutation analysis, FISH, NGS",High,Nuclear receptor,Increased AR gene copy number leads to resistance to next-generation hormonal therapies.,"TCGA, COSMIC",https://pubmed.ncbi.nlm.nih.gov/34716049/
Prostate,Hormonal therapy,Serum Testosterone,N/A,N/A,Response,"Serum assay (ELISA, chemiluminescence)",High,Steroid hormone,Higher baseline testosterone predicts better response to ADT.,GEO,https://pmc.ncbi.nlm.nih.gov/articles/PMC8616385/
Prostate,Hormonal therapy,Luminal B Subtype,Multiple,Transcriptional,Response,"RNA-seq, gene expression profiling",High,Mixed (various),Tumors with luminal B signature benefit from early hormone therapy.,"TCGA, GEO","https://www.pcf.org/news/scientists-identify-biomarkers-to-guide-hormone-therapy-for-prostate-cancer/, https://cancer.ucsf.edu/news/2017/05/11/scientists-identify-biomarkers-to-guide-hormone-therapy-for-prostate-cancer"
Prostate,Hormonal therapy,Basal Subtype,Multiple,Transcriptional,Non-response,"RNA-seq, gene expression profiling",High,Mixed (various),Basal subtype less likely to benefit from hormone therapy.,"TCGA, GEO","https://www.pcf.org/news/scientists-identify-biomarkers-to-guide-hormone-therapy-for-prostate-cancer/, https://cancer.ucsf.edu/news/2017/05/11/scientists-identify-biomarkers-to-guide-hormone-therapy-for-prostate-cancer"
Prostate,Hormonal therapy,PTEN Loss,PTEN,Deletion,Non-response,"IHC, FISH, NGS",High,Phosphatase,"PTEN loss leads to PI3K pathway activation, conferring resistance to ADT.","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8616385/
Prostate,Hormonal therapy,TP53 Mutation,TP53,Mutation,Non-response,"NGS, PCR",High,Tumor suppressor,TP53 mutations linked to poor response to hormonal therapy.,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8616385/
Prostate,Hormonal therapy,AR-V7 Splice Variant,AR,Splice variant,Non-response,"RT-PCR, NGS",High,Nuclear receptor,AR-V7 variant predicts resistance to enzalutamide/abiraterone.,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8616385/
Prostate,Hormonal therapy,PSA (Prostate-Specific Antigen),KLK3,Overexpression,Response,Serum assay (ELISA),High,Serine protease,PSA decline is a marker of response to hormonal therapy.,GEO,https://pmc.ncbi.nlm.nih.gov/articles/PMC8616385/
Prostate,Taxane,TUBB3,TUBB3,Amplification/Overexpression,Non-response,"IHC, RNA-seq",High,Structural protein,High TUBB3 (class III beta-tubulin) linked to taxane resistance by altering microtubule dynamics,"TCGA, COSMIC",https://www.carislifesciences.com/research/publications/taxane-sensitivity-markers-in-prostate-cancer/
Prostate,Taxane,ABCB1 (PGP),ABCB1,Amplification/Overexpression,Non-response,"IHC, RNA-seq, PCR",High,Transporter,"P-glycoprotein effluxes taxanes, reducing intracellular drug concentration","TCGA, COSMIC",https://www.carislifesciences.com/research/publications/taxane-sensitivity-markers-in-prostate-cancer/
Prostate,Taxane,AR (Androgen Receptor),AR,"Mutation, Rearrangement",Response,"IHC, RNA-seq, PCR, NGS",High,Nuclear receptor,AR-positive tumors more likely to respond to taxanes,"TCGA, COSMIC","https://ascopubs.org/doi/10.1200/jco.2016.34.2_suppl.285, https://pmc.ncbi.nlm.nih.gov/articles/PMC11564108/"
Prostate,Taxane,TP53,TP53,"Mutation, Deletion",Non-response,"NGS, PCR",High,Tumor suppressor,TP53 mutations linked to taxane resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC11564108/
Prostate,Taxane,Circulating Tumor Cells (CTCs),Multiple,N/A,Response/Non-response,"Liquid biopsy, CellSearch",High,N/A,CTC count reduction after taxane therapy predicts response,GEO,https://weillcornellgucancer.org/2017/10/09/treating-prostate-cancer-with-taxane-therapies-what-the-latest-research-shows/
Prostate,Taxane,PTEN,PTEN,"Deletion, Mutation",Non-response,"NGS, PCR, IHC",High,Tumor suppressor,"PTEN loss activates PI3K/AKT pathway, promoting resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7259995/
Prostate,Taxane,MDR1,ABCB1,Amplification,Non-response,"IHC, RNA-seq, PCR",High,Transporter,MDR1 overexpression leads to drug efflux and resistance,"TCGA, COSMIC",https://www.carislifesciences.com/research/publications/taxane-sensitivity-markers-in-prostate-cancer/
Skin Melanoma,Anti-PD-1,PD-L1,CD274,"Amplification, Expression",Response/Non-response,"IHC, RNA-seq, PCR",High,Immune checkpoint ligand,Inhibits T cell activation; high expression linked to immune evasion and response prediction,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1454720/full"
Skin Melanoma,Anti-PD-1,Tumor Mutational Burden (TMB),Multiple,Mutation,Response,Whole-exome sequencing,High,N/A (genomic feature),"High TMB increases neoantigen load, enhancing immune recognition","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/, https://jitc.bmj.com/content/10/7/e004879"
Skin Melanoma,Anti-PD-1,CD8+ T cell infiltration,N/A,N/A,Response,"IHC, RNA-seq",High,Immune cell marker,High infiltration predicts better response,"TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/, https://jitc.bmj.com/content/10/7/e004879"
Skin Melanoma,Immunotherapy,PD-L1,CD274,Amplification/Expression,Response,"IHC, RNA-seq",High,Immune checkpoint ligand,Inhibits T-cell activation; high expression predicts better response to PD-1/PD-L1 inhibitors,"TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC8070445/, https://www.curemelanoma.org/blog/how-biomarkers-are-used-in-melanoma"
Skin Melanoma,Immunotherapy,BRAF V600E,BRAF,Mutation,Response,"PCR, NGS",High,Kinase (enzyme),"Activates MAPK pathway; predicts response to BRAF/MEK inhibitors, less clear for immunotherapy","TCGA, COSMIC",https://www.curemelanoma.org/blog/how-biomarkers-are-used-in-melanoma
Skin Melanoma,Immunotherapy,TMB (Tumor Mutational Burden),Multiple,Mutation burden,Response,"WES, NGS",High,N/A (genomic feature),"High TMB increases neoantigen load, enhancing immunogenicity","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8070445/
Skin Melanoma,Immunotherapy,CD8+ TILs,CD8A,Infiltration,Response,"IHC, Flow cytometry",High,Surface glycoprotein,High infiltration correlates with better response to immunotherapy,"TCGA, GEO",https://www.mdpi.com/1422-0067/24/1/41
Skin Melanoma,Immunotherapy,T-cell Inflamed GEP,Multiple,Expression,Response,RNA-seq,High,N/A (gene signature),Reflects immune activation in tumor microenvironment,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC8070445/
Unknown primary (e.g. CUP),Chemotherapy,TP53,TP53,Mutation,Non-response,"NGS, Somatic Mutations",High,Tumor suppressor,Loss of function leads to chemoresistance and poor prognosis,"TCGA, COSMIC",https://ascopubs.org/doi/10.1200/OA-24-00041
Unknown primary (e.g. CUP),Chemotherapy,KRAS,KRAS,Mutation,Non-response,"NGS, PCR",High,GTPase (enzyme),"Activates downstream pathways, confers resistance to certain chemotherapies","TCGA, COSMIC",https://ascopubs.org/doi/10.1200/OA-24-00041
Unknown primary (e.g. CUP),Chemotherapy,BRAF V600E,BRAF,Mutation,Non-response,"NGS, PCR",High,Kinase (enzyme),"Constitutive MAPK pathway activation, linked to poor response","TCGA, COSMIC",https://ascopubs.org/doi/10.1200/OA-24-00041
Unknown primary (e.g. CUP),Chemotherapy,HER2/ERBB2,ERBB2,Amplification,Response,"IHC, FISH, NGS",High,Receptor tyrosine kinase,Overexpression predicts response to HER2-targeted therapy,"TCGA, COSMIC",https://ascopubs.org/doi/10.1200/OA-24-00041
Unknown primary (e.g. CUP),Chemotherapy,MSH2/MSH6,MSH2/MSH6,Mutation,Response,"NGS, IHC",High,DNA repair enzyme,"Deficiency leads to MSI-H, predicts response to immunotherapy","TCGA, COSMIC","https://pubmed.ncbi.nlm.nih.gov/29571084/, https://jitc.bmj.com/content/11/1/e005809"
Unknown primary (e.g. CUP),Chemotherapy,MLH1,MLH1,Mutation,Response,"NGS, IHC",High,DNA repair enzyme,"Loss leads to MSI-H, predicts response to immunotherapy","TCGA, COSMIC","https://pubmed.ncbi.nlm.nih.gov/29571084/, https://jitc.bmj.com/content/11/1/e005809"
Unknown primary (e.g. CUP),Chemotherapy,PD-L1,CD274,Overexpression,Response,IHC,High,Immune checkpoint,High expression predicts response to checkpoint inhibitors,"TCGA, GEO","https://pubmed.ncbi.nlm.nih.gov/29571084/, https://jitc.bmj.com/content/11/1/e005809"
Unknown primary (e.g. CUP),Chemotherapy,TMB (Tumor Mutational Burden),Multiple,High mutation load,Response,NGS,High,N/A,High TMB predicts response to immunotherapy,"TCGA, COSMIC","https://pubmed.ncbi.nlm.nih.gov/29571084/, https://jitc.bmj.com/content/11/1/e005809"
Unknown primary (e.g. CUP),Chemotherapy,MSI-H,Multiple,Genomic instability,Response,"NGS, PCR, IHC",High,N/A,High microsatellite instability predicts response to immunotherapy,"TCGA, COSMIC","https://pubmed.ncbi.nlm.nih.gov/29571084/, https://jitc.bmj.com/content/11/1/e005809"
Bladder Urothelial,Anti-PD-1,PD-1,PDCD1,Expression,Response,"IHC, RNA-seq",Medium,Immune checkpoint receptor,Regulates T-cell exhaustion; blockade restores T-cell function,"TCGA, COSMIC",https://einsteinmed.edu/uploadedFiles/Zang/UrologicOncology2017.pdf
Bladder Urothelial,Anti-PD-1,MSI (Microsatellite Instability),"MLH1, MSH2, MSH6, PMS2","Mutation, Deletion",Response,"PCR, NGS",Medium,DNA repair enzymes,Defective mismatch repair increases neoantigen load,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC10486227/, https://jitc.bmj.com/content/5/1/94"
Bladder Urothelial,Anti-PD-1,CD8+ TILs,N/A,Infiltration,Response,"IHC, Flow cytometry",Medium,Immune cell marker,High infiltration indicates active anti-tumor immunity,TCGA,"https://pmc.ncbi.nlm.nih.gov/articles/PMC10486227/, https://jitc.bmj.com/content/5/1/94"
Bladder Urothelial,Anti-PD-1,IFN-γ Signature,IFNG,Expression,Response,"RNA-seq, qPCR",Medium,Cytokine,Promotes anti-tumor immune response,"TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC10486227/, https://jitc.bmj.com/content/5/1/94"
Bladder Urothelial,Anti-PD-1,FGFR3 Mutation,FGFR3,Mutation,Non-response,"NGS, PCR",Medium,Receptor tyrosine kinase,"Associated with immune-cold tumors, poor response","TCGA, COSMIC",https://jitc.bmj.com/content/5/1/94
Bladder Urothelial,Anti-PD-1,TGF-β Signature,TGFB1,Expression,Non-response,"RNA-seq, qPCR",Medium,Cytokine,"Promotes immune exclusion, resistance to immunotherapy","TCGA, GEO",https://jitc.bmj.com/content/5/1/94
Bladder Urothelial,Anti-PD-1,APOBEC Signature,APOBEC3A/B,Mutation pattern,Response,"NGS, RNA-seq",Medium,Enzyme (cytidine deaminase),"Associated with higher mutational burden, increased immunogenicity","TCGA, COSMIC",https://jitc.bmj.com/content/5/1/94
Bladder Urothelial,Anti-PD-1,Circulating Tumor DNA (ctDNA),Multiple,"Mutation, Fragmentation",Response/Non-response,"NGS, PCR",Medium,N/A (cell-free DNA),"Reflects tumor burden and mutational landscape, dynamic marker","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10486227/
Bladder Urothelial,Immunotherapy,NECTIN4,NECTIN4,"Amplification, Expression",Response,"IHC, CNV analysis",Medium,Cell adhesion molecule,High expression predicts response to enfortumab vedotin (EV),TCGA,https://news.feinberg.northwestern.edu/2024/05/24/new-biomarker-may-predict-treatment-response-in-bladder-cancer/
Bladder Urothelial,Immunotherapy,FGFR3 mutation,FGFR3,Mutation,Non-response,"NGS, PCR",Medium,Receptor tyrosine kinase,"FGFR3 mutations linked to immune-cold phenotype, less ICI response","TCGA, COSMIC","https://jitc.bmj.com/content/5/1/94, https://pubmed.ncbi.nlm.nih.gov/29157296/"
Bladder Urothelial,Immunotherapy,DDR gene alterations,"ERCC2, ATM, RB1, FANCC",Mutation,Response,"NGS, PCR",Medium,DNA repair enzymes,"DDR mutations increase neoantigen load, improving ICI response","TCGA, COSMIC",https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01900/full
Bladder Urothelial,Immunotherapy,TGF-β pathway activation,"TGFB1, SMADs","Expression, Mutation",Non-response,"RNA-seq, IHC",Medium,"Cytokine, transcription factor","TGF-β signaling linked to immune exclusion, poor ICI response",TCGA,https://jitc.bmj.com/content/5/1/94
Bladder Urothelial,Immunotherapy,CTLA-4,CTLA4,Expression,Response/Non-response,"IHC, RNA-seq",Medium,Immune checkpoint,Modulates T-cell activation; variable association with ICI response,"TCGA, GEO","https://jitc.bmj.com/content/5/1/94, https://pubmed.ncbi.nlm.nih.gov/29157296/"
Bladder Urothelial,Immunotherapy,APOBEC mutational signature,APOBEC3A/B,"Mutation, Expression",Response,"NGS, RNA-seq",Medium,Cytidine deaminase,"APOBEC-driven mutations increase neoantigen load, enhancing immunogenicity","TCGA, COSMIC",https://jitc.bmj.com/content/5/1/94
Bladder Urothelial,Immunotherapy,IFN-γ signature,IFNG,Expression,Response,"RNA-seq, qPCR",Medium,Cytokine,High IFN-γ signaling linked to inflamed TME and better ICI response,"TCGA, GEO",https://jitc.bmj.com/content/5/1/94
Bladder Urothelial,Immunotherapy,MHC class I loss,HLA-A/B/C,"Deletion, Mutation",Non-response,"IHC, NGS",Medium,Antigen-presenting molecule,"Loss impairs antigen presentation, reducing ICI efficacy","TCGA, COSMIC",https://jitc.bmj.com/content/5/1/94
Breast ER+/HER-,Aromatase inhibitor,AKT1 Mutation,AKT1,Mutation,Non-response,"NGS, PCR",Medium,Enzyme (kinase),"Activates survival pathways, reducing AI efficacy","COSMIC, TCGA",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Aromatase inhibitor,CCND1 Amplification,CCND1,Amplification,Non-response,"FISH, PCR",Medium,Cell cycle regulator,"Promotes cell cycle progression, linked to resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Aromatase inhibitor,FGFR1 Amplification,FGFR1,Amplification,Non-response,"FISH, PCR",Medium,Receptor tyrosine kinase,"Drives proliferation, associated with poor AI response","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Aromatase inhibitor,BCL2 Expression,BCL2,Expression,Response,"IHC, RNA-seq",Medium,Anti-apoptotic protein,High BCL2 linked to better prognosis and response,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Aromatase inhibitor,Ki-67,MKI67,Expression,Non-response,IHC,Medium,Proliferation marker,"High Ki-67 indicates aggressive, less AI-responsive tumors","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Aromatase inhibitor,GATA3 Mutation,GATA3,Mutation,Response,"NGS, PCR",Medium,Transcription factor,"Maintains luminal phenotype, linked to endocrine sensitivity","COSMIC, TCGA",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Aromatase inhibitor,TP53 Mutation,TP53,Mutation,Non-response,"NGS, PCR",Medium,Tumor suppressor,Loss of function associated with resistance,"COSMIC, TCGA",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Aromatase inhibitor,CDK4/6 Pathway Alteration,CDK4/6,Amplification/Mutation,Non-response,"NGS, PCR",Medium,Cell cycle kinases,Dysregulation leads to AI resistance,"TCGA, COSMIC",https://www.icr.ac.uk/industry-partnerships/industry-partnerships-detail/opportunity--biomarker-for-cdk4-6-and-or-aromatase-inhibitor-response-in-breast-cancers
Breast ER+/HER-,Aromatase inhibitor,PTEN Loss,PTEN,Deletion/Mutation,Non-response,"IHC, NGS, PCR",Medium,Tumor suppressor,"Loss activates PI3K/AKT pathway, conferring resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Chemotherapy,Ki-67,MKI67,Expression,Non-response,IHC,Medium,Proliferation marker,"High levels indicate increased proliferation, linked to poor chemo response","TCGA, GEO",https://ascopubs.org/doi/10.1200/JCO.22.00069
Breast ER+/HER-,Chemotherapy,TP53 Mutation,TP53,Mutation,Non-response,Somatic mutation analysis,Medium,Tumor suppressor,"Loss of function impairs apoptosis, linked to resistance","TCGA, COSMIC",https://ascopubs.org/doi/10.1200/JCO.22.00069
Breast ER+/HER-,Chemotherapy,Cyclin D1,CCND1,Amplification,Non-response,"FISH, PCR, RNA-seq",Medium,Cell cycle regulator,"Promotes cell cycle progression, overexpression linked to resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Chemotherapy,BCL2,BCL2,Expression,Response,"IHC, RNA-seq",Medium,Anti-apoptotic,High expression linked to better prognosis and response,"TCGA, GEO",https://ascopubs.org/doi/10.1200/JCO.22.00069
Breast ER+/HER-,Chemotherapy,PIK3CA Mutation,PIK3CA,Mutation,Non-response,Somatic mutation analysis,Medium,Kinase,"Activates PI3K pathway, associated with resistance to some therapies","TCGA, COSMIC",https://ascopubs.org/doi/10.1200/JCO.22.00069
Breast ER+/HER-,Chemotherapy,RB1 Loss,RB1,Deletion/Mutation,Non-response,Somatic mutation analysis,Medium,Tumor suppressor,"Loss leads to unchecked cell cycle, linked to resistance","TCGA, COSMIC",https://ascopubs.org/doi/10.1200/JCO.22.00069
Breast ER+/HER-,Chemotherapy,GATA3,GATA3,Mutation,Response,Somatic mutation analysis,Medium,Transcription factor,"Maintains luminal phenotype, mutations linked to better response","TCGA, COSMIC",https://ascopubs.org/doi/10.1200/JCO.22.00069
Breast ER+/HER-,Chemotherapy,CDK4,CDK4,Amplification,Non-response,"FISH, PCR",Medium,Kinase,"Promotes cell cycle progression, overexpression linked to resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Chemotherapy,MYC,MYC,Amplification,Non-response,"FISH, PCR",Medium,Transcription factor,"Drives proliferation, overexpression linked to resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Chemotherapy,TILs (Tumor-Infiltrating Lymphocytes),N/A,N/A,Response,"IHC, Histopathology",Medium,Immune cells,High TILs linked to better response to chemotherapy,"TCGA, GEO",https://ascopubs.org/doi/10.1200/JCO.22.00069
Breast ER+/HER-,Chemotherapy,ESR1 Mutation,ESR1,Mutation,Non-response,Somatic mutation analysis,Medium,Nuclear receptor,Mutations confer resistance to endocrine therapy,"TCGA, COSMIC",https://ascopubs.org/doi/10.1200/JCO.22.00069
Breast ER+/HER-,Hormonal therapy,Ki-67,MKI67,Expression,Non-response,IHC,Medium,Proliferation marker,High proliferation index linked to poor response,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC11564209/
Breast ER+/HER-,Hormonal therapy,BCL2,BCL2,Expression,Response,"IHC, RNA-seq",Medium,Anti-apoptotic protein,High expression associated with favorable prognosis and response,"TCGA, GEO",https://www.jcancer.org/v07p1281.htm
Breast ER+/HER-,Hormonal therapy,BRCA1/2,BRCA1/2,Mutation,Non-response,"PCR, NGS",Medium,DNA repair enzyme,Mutations may confer resistance to hormonal therapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC11564209/
Breast ER+/HER-,Hormonal therapy,AKT1,AKT1,Mutation,Non-response,"NGS, PCR",Medium,Kinase (enzyme),"Mutations activate survival pathways, reducing therapy efficacy","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Hormonal therapy,TP53,TP53,Mutation,Non-response,"NGS, PCR",Medium,Tumor suppressor,Mutations linked to endocrine resistance,"TCGA, COSMIC",https://www.jcancer.org/v07p1281.htm
Breast ER+/HER-,Hormonal therapy,FGFR1,FGFR1,Amplification,Non-response,"FISH, NGS",Medium,Receptor tyrosine kinase,Amplification associated with resistance to endocrine therapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Hormonal therapy,CCND1,CCND1,Amplification,Non-response,"FISH, NGS",Medium,Cell cycle regulator,Amplification leads to cell cycle progression and resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Hormonal therapy,GATA3,GATA3,Mutation,Response,"NGS, PCR",Medium,Transcription factor,"Mutations often co-occur with ER+ status, associated with better response","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Hormonal therapy,BCL2,BCL2,Expression,Response,"IHC, RNA-seq",Medium,Anti-apoptotic protein,High expression linked to favorable prognosis and response in ER+ tumors,"TCGA, GEO",https://www.jcancer.org/v07p1281.htm
Breast ER+/HER-,Hormonal therapy,Ki-67,MKI67,Expression,Non-response,IHC,Medium,Proliferation marker,"High Ki-67 indicates high proliferation, associated with poor response","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC11564209/
Breast ER+/HER-,Hormonal therapy,BRCA1/2,BRCA1/2,Mutation,Non-response,"PCR, Sequencing",Medium,DNA repair enzyme,Mutations may confer resistance to hormonal therapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC11564209/
Breast ER+/HER-,Hormonal therapy,AKT1,AKT1,Mutation,Non-response,"Sequencing, PCR",Medium,Kinase (PI3K pathway),Mutations associated with resistance to hormonal therapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Hormonal therapy,GATA3,GATA3,Mutation,Response,"Sequencing, PCR",Medium,Transcription factor,"Mutations often co-occur with ER+ status, linked to better response","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Hormonal therapy,FGFR1,FGFR1,Amplification,Non-response,"FISH, PCR",Medium,Receptor tyrosine kinase,Amplification associated with endocrine resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Hormonal therapy,CCND1,CCND1,Amplification,Non-response,"FISH, PCR",Medium,Cell cycle regulator,Amplification linked to resistance to hormonal therapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Pyrimidine (ant)agonist,MTHFR,MTHFR,Mutation,Non-response,"PCR, SNP genotyping",Medium,Enzyme (Methylenetetrahydrofolate reductase),Folate metabolism; polymorphisms affect 5-FU efficacy,"TCGA, GEO",https://research.rug.nl/files/2914175/thesis.pdf
Breast ER+/HER-,Pyrimidine (ant)agonist,UMPS,UMPS,"Mutation, Deletion",Non-response,"RNA-seq, PCR",Medium,Enzyme (Uridine monophosphate synthetase),Pyrimidine biosynthesis; loss reduces 5-FU activation,"TCGA, COSMIC",https://research.rug.nl/files/2914175/thesis.pdf
Breast ER+/HER-,Pyrimidine (ant)agonist,RRM1,RRM1,Amplification,Non-response,"RNA-seq, IHC",Medium,Enzyme (Ribonucleotide reductase M1),dNTP synthesis; high levels confer resistance to nucleoside analogs,"TCGA, COSMIC",https://research.rug.nl/files/2914175/thesis.pdf
Breast ER+/HER-,Pyrimidine (ant)agonist,CDA,CDA,"Mutation, Deletion",Non-response,"PCR, RNA-seq",Medium,Enzyme (Cytidine deaminase),Inactivates cytidine analogs; loss increases toxicity,"TCGA, COSMIC",https://research.rug.nl/files/2914175/thesis.pdf
Breast ER+/HER-,Pyrimidine (ant)agonist,DCK,DCK,"Mutation, Deletion",Non-response,"RNA-seq, PCR",Medium,Enzyme (Deoxycytidine kinase),Activates nucleoside analogs; loss confers resistance,"TCGA, COSMIC",https://research.rug.nl/files/2914175/thesis.pdf
Breast ER+/HER-,Pyrimidine (ant)agonist,CAD,CAD,Amplification,Non-response,"RNA-seq, IHC",Medium,"Enzyme (Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, dihydroorotase)",Pyrimidine biosynthesis; upregulation linked to resistance,"TCGA, COSMIC",https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.684961/full
Breast ER+/HER-,Pyrimidine (ant)agonist,DHODH,DHODH,"Mutation, Amplification",Response,"RNA-seq, PCR",Medium,Enzyme (Dihydroorotate dehydrogenase),Target of pyrimidine antagonists; inhibition sensitizes tumors,"TCGA, COSMIC",https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.684961/full
Breast ER+/HER-,Pyrimidine (ant)agonist,BRAF (V600E),BRAF,Mutation,Response,Somatic Mutation,Medium,Kinase (Ser/Thr kinase),"Oncogenic driver; increases pyrimidine dependence, synthetic lethality w/ DHODH","TCGA, COSMIC",https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.684961/full
Breast ER+/HER-,Pyrimidine (ant)agonist,PTEN,PTEN,"Deletion, Mutation",Response,"IHC, Somatic Mutation",Medium,Phosphatase,"Loss increases pyrimidine pathway dependence, sensitizes to DHODH inhibitors","TCGA, COSMIC",https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.684961/full
Breast ER+/HER-,Pyrimidine (ant)agonist,KRAS,KRAS,Mutation,Response,Somatic Mutation,Medium,GTPase,"Oncogenic driver; increases pyrimidine dependence, synthetic lethality w/ DHODH","TCGA, COSMIC",https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.684961/full
Breast ER+/HER-,Pyrimidine (ant)agonist,INOSINE,N/A,Metabolic alteration,Response,Metabolomics (LC-MS/MS),Medium,Metabolite,Plasma levels predict chemotherapy response in breast cancer,"GEO, Metabolomics",https://pmc.ncbi.nlm.nih.gov/articles/PMC11381768/
Breast ER+/HER-,Pyrimidine (ant)agonist,URIDINE,N/A,Metabolic alteration,Response,Metabolomics (LC-MS/MS),Medium,Metabolite,Plasma levels predict chemotherapy response in breast cancer,"GEO, Metabolomics",https://pmc.ncbi.nlm.nih.gov/articles/PMC11381768/
Breast ER+/HER-,Pyrimidine (ant)agonist,PMI Signature,Multi-gene,Transcriptomic signature,Non-response,"RNA-seq, Transcriptomics",Medium,Multi-gene signature,High PMI score linked to poor prognosis and altered immune microenvironment,"TCGA, METABRIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC9745154/
Breast Triple Negative,Chemotherapy,EGFR,EGFR,Amplification,Non-response,"IHC, FISH, PCR",Medium,Receptor tyrosine kinase,"Overexpression associated with aggressive phenotype, poor chemo response","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC4675910/
Breast Triple Negative,Chemotherapy,TMB,N/A,N/A,Response,"NGS, WES",Medium,Genomic feature,High TMB linked to improved response to chemo-immunotherapy,"TCGA, COSMIC","https://www.oncologynewscentral.com/breast-cancer/biomarkers-linked-to-pathologic-response-in-early-triple-negative-breast-cancer, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.779786/full"
Breast Triple Negative,Chemotherapy,PIK3CA,PIK3CA,Mutation,Non-response,"Somatic Mutations, PCR",Medium,Enzyme (kinase),Mutations associated with resistance to chemotherapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7369987/
Breast Triple Negative,Chemotherapy,PTEN,PTEN,Deletion/Mutation,Non-response,"IHC, PCR",Medium,Tumor suppressor,Loss linked to chemoresistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7369987/
Breast Triple Negative,Chemotherapy,c-MYC,MYC,Amplification,Non-response,"FISH, PCR",Medium,Transcription factor,Overexpression linked to poor chemo response,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC4675910/
Breast Triple Negative,Chemotherapy,CK5/6,KRT5/KRT6,Overexpression,Non-response,IHC,Medium,Structural protein,"Basal cytokeratin expression linked to aggressive, chemo-resistant phenotype","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC4675910/
Breast Triple Negative,Chemotherapy,VEGF,VEGFA,Overexpression,Non-response,"IHC, ELISA",Medium,Growth factor,"Promotes angiogenesis, associated with poor chemo response","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC4675910/
Breast Triple Negative,Chemotherapy,PARP1,PARP1,Overexpression,Response,"IHC, PCR",Medium,DNA repair enzyme,"Targeted by PARP inhibitors, synthetic lethality in BRCA-mutant TNBC","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC4675910/
Colon,Chemotherapy,NRAS,NRAS,Mutation,Non-response,"Somatic mutation (PCR, NGS)",Medium,GTPase (enzyme),"Activates MAPK pathway, associated with anti-EGFR resistance","TCGA, COSMIC",https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,TYMS,TYMS,Overexpression,Non-response,"IHC, qPCR, RNA-seq",Medium,Enzyme,High levels reduce efficacy of 5-FU chemotherapy,"GEO, TCGA",https://pmc.ncbi.nlm.nih.gov/articles/PMC6288499/
Colon,Chemotherapy,DPYD,DPYD,Mutation,Non-response,"Somatic mutation (PCR, NGS)",Medium,Enzyme,"Deficiency leads to 5-FU toxicity, poor response","TCGA, COSMIC",https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,TP53,TP53,Mutation,Non-response,"Somatic mutation (PCR, NGS)",Medium,Transcription factor,"Loss of function impairs apoptosis, reduces chemotherapy efficacy","TCGA, COSMIC",https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,EGFR,EGFR,Overexpression,Non-response,"IHC, qPCR, RNA-seq",Medium,Receptor tyrosine kinase,Overexpression linked to resistance to anti-EGFR therapy,"TCGA, COSMIC",https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.1062423/full
Colon,Chemotherapy,10-gene signature,Multiple,Expression profile,Response/Non-response,"RNA-seq, qPCR",Medium,Mixed,Predicts benefit from adjuvant chemotherapy in stage II/III colon cancer,"TCGA, GEO","https://news.med.miami.edu/colon-cancer-biomarkers/, https://www.news-medical.net/news/20240727/New-biomarker-helps-determine-the-optimal-treatment-for-colon-cancer.aspx"
Colon,Chemotherapy,PIK3CA,PIK3CA,Mutation,Non-response,"Somatic mutation (PCR, NGS)",Medium,Enzyme,"Activates PI3K pathway, associated with resistance to anti-EGFR therapy","TCGA, COSMIC",https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,VEGFA,VEGFA,Overexpression,Non-response,"IHC, qPCR, RNA-seq",Medium,Growth factor,"Promotes angiogenesis, associated with resistance to anti-angiogenic therapy","TCGA, GEO",https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,HER2 amplification,ERBB2,Amplification,Non-response,"FISH, IHC, NGS",Medium,Receptor tyrosine kinase,"Bypasses EGFR blockade, confers resistance to anti-EGFR therapy","TCGA, COSMIC",https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.1062423/full
Colon,Chemotherapy,TP53 mutation,TP53,Mutation,Non-response,"PCR, NGS",Medium,Tumor suppressor,"Loss of cell cycle control, associated with poor response to some chemotherapies","TCGA, COSMIC",https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,10-gene signature,Multiple,Expression change,Response/Non-response,"RNA-seq, qPCR",Medium,Various,Predicts benefit from adjuvant chemotherapy in stage II/III colon cancer,"TCGA, GEO","https://news.med.miami.edu/colon-cancer-biomarkers/, https://www.news-medical.net/news/20240727/New-biomarker-helps-determine-the-optimal-treatment-for-colon-cancer.aspx"
Colon,Chemotherapy,CEA,CEACAM5,Overexpression,Non-response,"IHC, ELISA",Medium,Cell adhesion molecule,High levels linked to poor prognosis and reduced chemo benefit,TCGA,https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,NRAS mutation,NRAS,Mutation,Non-response,"PCR, NGS",Medium,GTPase (enzyme),"Activates MAPK pathway, resistance to anti-EGFR therapy","TCGA, COSMIC",https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,PIK3CA mutation,PIK3CA,Mutation,Non-response,"PCR, NGS",Medium,Kinase (enzyme),"Activates PI3K pathway, may reduce chemo efficacy","TCGA, COSMIC",https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,EGFR expression,EGFR,Overexpression,Response,"IHC, qPCR",Medium,Receptor tyrosine kinase,"Target for anti-EGFR therapy, higher expression may predict response","TCGA, COSMIC","https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.1062423/full, https://www.mdpi.com/2072-6694/16/16/2796"
Colon,Chemotherapy,APC mutation,APC,Mutation,Non-response,"PCR, NGS",Medium,Tumor suppressor,"Wnt pathway activation, associated with poor prognosis","TCGA, COSMIC",https://www.mdpi.com/2072-6694/16/16/2796
Gastroesophageal,Chemotherapy,FGFR2,FGFR2,Amplification,Response,"FISH, NGS",Medium,Receptor tyrosine kinase,FGFR2 amplification predicts response to FGFR inhibitors[2].,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10380533/
Gastroesophageal,Chemotherapy,CLDN18.2,CLDN18,Overexpression,Response,IHC,Medium,Tight junction protein,Overexpression predicts response to claudin 18.2-targeted therapies[2].,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10380533/
Gastroesophageal,Chemotherapy,EGFR,EGFR,"Amplification, Mutation",Non-response,"IHC, FISH, NGS",Medium,Receptor tyrosine kinase,EGFR alterations may confer resistance to some chemotherapies[4].,"TCGA, COSMIC",https://www.wjgnet.com/1948-5204/full/v11/i7/518.htm
Gastroesophageal,Chemotherapy,TP53,TP53,Mutation,Non-response,"NGS, PCR",Medium,Tumor suppressor,TP53 mutations often linked to poor response to chemotherapy[4].,"TCGA, COSMIC",https://www.wjgnet.com/1948-5204/full/v11/i7/518.htm
Gastroesophageal,Chemotherapy,MET,MET,Amplification,Non-response,"FISH, NGS",Medium,Receptor tyrosine kinase,MET amplification associated with resistance to standard chemotherapy[2].,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10380533/
Gastroesophageal,Chemotherapy,ERCC1,ERCC1,Overexpression,Non-response,"IHC, qPCR",Medium,DNA repair enzyme,High ERCC1 expression linked to resistance to platinum-based chemotherapy[2].,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10380533/
Gastroesophageal,Chemotherapy,Thymidylate Synthase (TS),TYMS,Overexpression,Non-response,"IHC, qPCR",Medium,Enzyme,High TS expression predicts resistance to fluoropyrimidines[2].,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10380533/
Gastroesophageal,Chemotherapy,Circulating Tumor DNA (ctDNA),Various,Somatic Mutations,Response/Non-response,"NGS, digital PCR",Medium,N/A (biomarker type),ctDNA dynamics reflect response or resistance to therapy[3].,"TCGA, GEO",https://ascopubs.org/doi/10.1200/EDBK_431060
Gastroesophageal,Chemotherapy,E-cadherin,CDH1,"Mutation, Deletion",Non-response,"IHC, NGS",Medium,Cell adhesion protein,Loss of E-cadherin linked to poor prognosis and chemoresistance[4].,"TCGA, COSMIC",https://www.wjgnet.com/1948-5204/full/v11/i7/518.htm
Kidney,Multikinase inhibitor,PBRM1,PBRM1,Mutation,Response,Somatic mutation analysis (NGS),Medium,Chromatin remodeler,Mutations linked to improved response to VEGF-TKIs and immunotherapy,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC10419620/, https://ascopubs.org/doi/10.1200/EDBK_430734"
Kidney,Multikinase inhibitor,BAP1,BAP1,Mutation,Non-response,Somatic mutation analysis (NGS),Medium,Deubiquitinase,Associated with aggressive disease and poor response to TKIs,"TCGA, COSMIC",https://ascopubs.org/doi/10.1200/EDBK_430734
Kidney,Multikinase inhibitor,PD-L1,CD274,Amplification/Expression,Non-response,"IHC, RNA-seq",Medium,Immune checkpoint ligand,"High expression linked to immune evasion, may predict poor response to TKIs","TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC10419620/, https://ascopubs.org/doi/10.1200/EDBK_430734"
Kidney,Multikinase inhibitor,VEGFA,VEGFA,Amplification,Response,"RNA-seq, qPCR",Medium,Growth factor,"Overexpression drives angiogenesis, target of VEGF-TKIs","TCGA, GEO",https://ascopubs.org/doi/10.1200/EDBK_430734
Kidney,Multikinase inhibitor,HIF1A,HIF1A,Stabilization,Response,"IHC, RNA-seq",Medium,Transcription factor,"Upregulated in VHL loss, promotes angiogenesis, targetable by TKIs","TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC10419620/, https://ascopubs.org/doi/10.1200/EDBK_430734"
Kidney,Multikinase inhibitor,FGFR1,FGFR1,Amplification,Non-response,"NGS, FISH, IHC",Medium,Receptor tyrosine kinase,FGFR pathway activation associated with resistance to VEGF-TKIs,"TCGA, COSMIC",https://ascopubs.org/doi/10.1200/EDBK_430734
Kidney,Multikinase inhibitor,mTOR,MTOR,Mutation,Non-response,NGS,Medium,Serine/threonine kinase,mTOR pathway activation linked to resistance to VEGF-TKIs,"TCGA, COSMIC",https://ascopubs.org/doi/10.1200/EDBK_430734
Kidney,Multikinase inhibitor,TP53,TP53,Mutation,Non-response,NGS,Medium,Tumor suppressor,TP53 mutations linked to poor prognosis and resistance to therapy,"TCGA, COSMIC",https://ascopubs.org/doi/10.1200/EDBK_430734
Kidney,Multikinase inhibitor,ctDNA,Various,Mutation,Non-response,"Liquid biopsy (NGS, PCR)",Medium,N/A (multiple genes),High ctDNA levels correlate with progressive disease and non-response,"TCGA, COSMIC",https://www.urologytimes.com/view/exploring-the-potential-role-of-ctdna-as-a-biomarker-in-kidney-cancer
Kidney,Multikinase inhibitor,CA9,CA9,Overexpression,Response,"IHC, RNA-seq",Medium,Enzyme (carbonic anhydrase),"CA9 overexpression linked to VHL loss, may predict response to VEGF-TKIs","TCGA, GEO",https://ascopubs.org/doi/10.1200/EDBK_430734
Kidney,Targeted therapy,HIF2α (EPAS1),EPAS1,Mutation,Response/Resistance,"RNA-seq, NGS",Medium,Transcription factor,Target of HIF2α inhibitors; mutations may confer resistance,"TCGA, COSMIC",https://ascopubs.org/doi/10.1200/EDBK_430734
Kidney,Targeted therapy,CA9,CA9,Overexpression,Response,"IHC, RNA-seq",Medium,Enzyme (carbonic anhydrase),"HIF target; marker of hypoxia, may predict response to HIF2α inhibitors","TCGA, GEO",https://ascopubs.org/doi/10.1200/EDBK_430734
Kidney,Targeted therapy,PD-L1,CD274,Overexpression,Response/Non-response,"IHC, RNA-seq",Medium,Immune checkpoint ligand,Predicts response to immune checkpoint inhibitors (ICIs),"TCGA, GEO",https://actionkidneycancer.org/the-role-of-biomarkers-in-predicting-response-to-treatment-in-metastatic-kidney-cancer/
Kidney,Targeted therapy,PD-1,PDCD1,Overexpression,Response/Non-response,"IHC, RNA-seq",Medium,Immune checkpoint receptor,Predicts response to ICIs,"TCGA, GEO",https://actionkidneycancer.org/the-role-of-biomarkers-in-predicting-response-to-treatment-in-metastatic-kidney-cancer/
Kidney,Targeted therapy,VEGFA,VEGFA,Overexpression,Response,"RNA-seq, IHC",Medium,Growth factor,"Target of VEGF inhibitors (e.g., sunitinib, pazopanib)","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10645469/
Kidney,Targeted therapy,PBRM1,PBRM1,Mutation,Response/Non-response,"NGS, PCR",Medium,Chromatin remodeler,Mutations may predict response to ICIs,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10645469/
Kidney,Targeted therapy,BAP1,BAP1,Mutation,Non-response,"NGS, PCR",Medium,Deubiquitinase,"Mutations linked to poor prognosis, resistance to some therapies","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10645469/
Kidney,Targeted therapy,mTOR,MTOR,"Mutation, Activation",Response,"NGS, IHC",Medium,Kinase,"Target of mTOR inhibitors (e.g., everolimus)","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10645469/
Kidney,Targeted therapy,TSC1/TSC2,TSC1/TSC2,Mutation,Response,"NGS, PCR",Medium,Tumor suppressor,Mutations predict response to mTOR inhibitors,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10645469/
Lung NSCLC,Anti-PD-1,sPD-1 (soluble PD-1),PDCD1,Splice variant,Response,ELISA (serum),Medium,Immune checkpoint receptor,Downregulation in responders; modulates immune activation,GEO,https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1157100/full
Lung NSCLC,Anti-PD-1,STK11/LKB1 Mutation,STK11,Mutation,Non-response,"NGS, PCR",Medium,Kinase,"Loss impairs immune response, linked to resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10351040/
Lung NSCLC,Anti-PD-1,KEAP1 Mutation,KEAP1,Mutation,Non-response,"NGS, PCR",Medium,Regulatory protein,"Alters oxidative stress response, associated with resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10351040/
Lung NSCLC,Anti-PD-1,IFN-γ Signature,IFNG,Expression,Response,"RNA-seq, qPCR",Medium,Cytokine,High IFN-γ signature correlates with response,"TCGA, GEO",https://pubmed.ncbi.nlm.nih.gov/36822668/
Lung NSCLC,Anti-PD-1,HLA Class I Loss,HLA-A/B/C,Deletion/Mutation,Non-response,"NGS, IHC",Medium,Antigen-presenting molecule,"Loss impairs antigen presentation, leading to immune evasion","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10351040/
Lung NSCLC,Anti-PD-1,PTEN Loss,PTEN,Deletion/Mutation,Non-response,"NGS, IHC",Medium,Phosphatase,Loss leads to immune suppression and resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10351040/
Lung NSCLC,Chemotherapy,ERCC1,ERCC1,Mutation/Expression,Non-response,"IHC, PCR, RNA-seq",Medium,DNA repair enzyme,High ERCC1 expression linked to resistance to platinum-based chemotherapy,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC6025105/
Lung NSCLC,Chemotherapy,RRM1,RRM1,Expression,Non-response,"IHC, PCR, RNA-seq",Medium,Enzyme,High RRM1 expression associated with gemcitabine resistance,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC6025105/
Lung NSCLC,Chemotherapy,BRCA1,BRCA1,Mutation/Expression,Response,"IHC, PCR, RNA-seq",Medium,Tumor suppressor,High BRCA1 expression may predict better response to platinum agents,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6025105/
Lung NSCLC,Chemotherapy,TYMS,TYMS,Expression,Non-response,"IHC, PCR, RNA-seq",Medium,Enzyme,High TYMS expression linked to resistance to pemetrexed and 5-FU,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC6025105/
Lung NSCLC,Chemotherapy,TP53,TP53,Mutation,Non-response,"NGS, PCR",Medium,Tumor suppressor,TP53 mutations often linked to poor prognosis and chemo resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6025105/
Lung NSCLC,Chemotherapy,KRAS,KRAS,Mutation,Non-response,"PCR, NGS",Medium,GTPase,KRAS mutations associated with poor response to chemotherapy,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC6025105/, https://www.frontiersin.org/journals/oncology-reviews/articles/10.3389/or.2024.1445826/full"
Lung NSCLC,Chemotherapy,TUBB3,TUBB3,Expression,Non-response,"IHC, PCR",Medium,Structural protein,High TUBB3 expression linked to taxane resistance,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC6025105/
Lung NSCLC,Chemotherapy,MSH2,MSH2,Mutation/Expression,Non-response,"IHC, PCR, NGS",Medium,DNA repair enzyme,Mismatch repair deficiency linked to chemo resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6025105/
Lung NSCLC,Chemotherapy,MET,MET,Amplification,Non-response,"FISH, NGS, PCR",Medium,Receptor tyrosine kinase,MET amplification linked to poor chemo response and resistance,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC6025105/, https://www.frontiersin.org/journals/oncology-reviews/articles/10.3389/or.2024.1445826/full"
Lung NSCLC,Immunotherapy,STK11/LKB1 Mutation,STK11,Mutation,Non-response,"NGS, PCR",Medium,Serine/threonine kinase,"Loss impairs immune infiltration, confers resistance","TCGA, COSMIC",https://pcm.amegroups.org/article/view/7603/html
Lung NSCLC,Immunotherapy,LDH,LDHA,Expression,Non-response,Serum assay,Medium,Enzyme,"High LDH reflects tumor proliferation, linked to poor ICI response",GEO,"https://pcm.amegroups.org/article/view/7603/html, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1489977/full"
Lung NSCLC,Immunotherapy,Interferon-γ,IFNG,Expression,Response,"ELISA, RNA-seq",Medium,Cytokine,"Promotes anti-tumor immunity, higher levels linked to better response",GEO,https://pcm.amegroups.org/article/view/7603/html
Lung NSCLC,Immunotherapy,Neutrophil-to-Lymphocyte Ratio (NLR),N/A,N/A,Non-response,CBC (blood test),Medium,N/A (cell ratio),"High NLR indicates systemic inflammation, predicts poor ICI response",GEO,https://pcm.amegroups.org/article/view/7603/html
Lung NSCLC,Immunotherapy,sPD-L1 (soluble),CD274,Expression,Non-response,ELISA,Medium,Immune checkpoint ligand,High sPD-L1 in plasma linked to worse outcomes,GEO,"https://pmc.ncbi.nlm.nih.gov/articles/PMC10418476/, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1489977/full"
Lung NSCLC,Immunotherapy,IL-6,IL6,Expression,Non-response,ELISA,Medium,Cytokine,High IL-6 associated with immunotherapy resistance,GEO,https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1489977/full
Lung NSCLC,Immunotherapy,IL-8,CXCL8,Expression,Non-response,ELISA,Medium,Chemokine,High IL-8 linked to resistance and poor survival,GEO,https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1489977/full
Lung NSCLC,Immunotherapy,CXCL10,CXCL10,Expression,Non-response,ELISA,Medium,Chemokine,High CXCL10 associated with resistance and inferior outcomes,GEO,https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1489977/full
Ovary,Chemotherapy,FGF1,FGF1,Amplification,Non-response,"CGH, qPCR, IHC",Medium,Growth factor,Amplification linked to poor survival and chemoresistance,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC3381792/
Ovary,Chemotherapy,CT45,CT45,Overexpression,Response,"RNA-seq, IHC",Medium,Cancer/testis antigen,High expression linked to improved response to platinum chemotherapy,TCGA,https://www.uchicagomedicine.org/forefront/cancer-articles/2018/september/novel-biomarker-found-in-ovarian-cancer-patients-can-predict-response-to-therapy
Ovary,Chemotherapy,ERCC1,ERCC1,Overexpression,Non-response,"qPCR, IHC",Medium,DNA repair enzyme,High levels confer resistance to platinum-based chemotherapy,"TCGA, GEO",https://erc.bioscientifica.com/view/journals/erc/25/5/ERC-17-0336.xml
Ovary,Chemotherapy,ABCB1 (MDR1),ABCB1,Amplification,Non-response,"qPCR, IHC",Medium,Transporter,Drug efflux pump; overexpression leads to multidrug resistance,"TCGA, COSMIC",https://erc.bioscientifica.com/view/journals/erc/25/5/ERC-17-0336.xml
Ovary,Chemotherapy,TP53,TP53,Mutation,Non-response,"NGS, IHC",Medium,Tumor suppressor,Mutations associated with chemoresistance in some ovarian cancer subtypes,"TCGA, COSMIC",https://erc.bioscientifica.com/view/journals/erc/25/5/ERC-17-0336.xml
Ovary,Chemotherapy,ARID1A,ARID1A,Mutation,Non-response,"NGS, IHC",Medium,Chromatin remodeler,Loss-of-function mutations associated with platinum resistance,"TCGA, COSMIC",https://erc.bioscientifica.com/view/journals/erc/25/5/ERC-17-0336.xml
Ovary,Chemotherapy,MMR Deficiency,MLH1/MSH2,Mutation/Deletion,Response,"IHC, PCR, MSI testing",Medium,DNA repair enzymes,Deficiency predicts response to immunotherapy and possibly platinum,"TCGA, COSMIC",https://www.targetedonc.com/view/the-role-of-biomarker-testing-in-ovarian-cancer
Ovary,Chemotherapy,93-gene signature,Multiple,Expression,Response,"RNA-seq, microarray",Medium,Mixed,Predicts pathologic complete response to chemotherapy,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC3381792/
Pan-Cancer,Alkaloid,β-tubulin,TUBB,Mutation,Non-response,"Somatic Mutations, IHC",Medium,Structural protein,Mutations confer resistance to microtubule-targeting alkaloids,"COSMIC, TCGA",https://pmc.ncbi.nlm.nih.gov/articles/PMC8716855/
Pan-Cancer,Alkaloid,BCL2,BCL2,Amplification,Non-response,"IHC, RNA-seq",Medium,Anti-apoptotic,"Overexpression inhibits apoptosis, reducing alkaloid efficacy","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC8716855/
Pan-Cancer,Alkaloid,MDM2,MDM2,Amplification,Non-response,"IHC, RNA-seq, PCR",Medium,E3 ligase,"Inhibits p53, reducing apoptosis and drug response","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8716855/
Pan-Cancer,Alkaloid,ERCC1,ERCC1,Amplification,Non-response,"RNA-seq, PCR",Medium,DNA repair protein,"High expression repairs alkaloid-induced DNA damage, reducing efficacy","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC8716855/
Pan-Cancer,Alkaloid,GSTP1,GSTP1,Amplification,Non-response,"RNA-seq, PCR",Medium,Detoxification enzyme,"Detoxifies alkaloid drugs, leading to resistance","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC8716855/
Pan-Cancer,Alkaloid,HDAC1,HDAC1,Amplification,Non-response,"RNA-seq, IHC, PCR",Medium,Enzyme,"Alters chromatin, can mediate resistance to alkaloid-induced apoptosis","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10813144/
Pan-Cancer,Alkaloid,EGFR,EGFR,Amplification,Non-response,"IHC, RNA-seq, PCR",Medium,Receptor tyrosine kinase,"Activation promotes survival pathways, reducing alkaloid efficacy","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8716855/
Pan-Cancer,Alkaloid,NF-κB,RELA,Activation,Non-response,"IHC, RNA-seq",Medium,Transcription factor,"Promotes survival and inflammation, counteracting alkaloid-induced apoptosis","TCGA, GEO",https://pubs.rsc.org/en/content/articlehtml/2025/ra/d4ra05089d
Pan-Cancer,Alkaloid,Caspase-3,CASP3,Disruption,Non-response,"IHC, RNA-seq",Medium,Protease,"Loss impairs apoptosis, reducing alkaloid efficacy","TCGA, GEO",https://pubs.rsc.org/en/content/articlehtml/2025/ra/d4ra05089d
Pan-Cancer,Alkaloid,Wnt/β-catenin,CTNNB1,Activation,Non-response,"IHC, RNA-seq",Medium,Transcription factor,"Activation promotes resistance to apoptosis, reducing alkaloid efficacy","TCGA, GEO",https://pubs.rsc.org/en/content/articlehtml/2025/ra/d4ra05089d
Pan-Cancer,Alkylating,miR-181a,MIR181A1,Upregulation,Response,"qRT-PCR, RNA-seq",Medium,microRNA,"Suppresses MGMT, increases sensitivity to alkylating agents.",GEO,https://pmc.ncbi.nlm.nih.gov/articles/PMC9019174/
Pan-Cancer,Alkylating,miR-18a,MIR18A1,Upregulation,Non-response,"qRT-PCR, RNA-seq",Medium,microRNA,Associated with shorter overall survival after alkylating therapy.,GEO,https://pmc.ncbi.nlm.nih.gov/articles/PMC9019174/
Pan-Cancer,Alkylating,miR-222,MIR222,Upregulation,Non-response,"qRT-PCR, RNA-seq",Medium,microRNA,Linked to shorter progression-free survival after alkylating therapy.,GEO,https://pmc.ncbi.nlm.nih.gov/articles/PMC9019174/
Pan-Cancer,Alkylating,miR-221,MIR221,Upregulation,Non-response,"qRT-PCR, RNA-seq",Medium,microRNA,Upregulated in poor responders to cyclophosphamide-based therapy.,GEO,https://pmc.ncbi.nlm.nih.gov/articles/PMC9019174/
Pan-Cancer,Alkylating,miR-93,MIR93,Upregulation,Non-response,"qRT-PCR, RNA-seq",Medium,microRNA,"Targets apoptosis regulators, upregulated in poor responders.",GEO,https://pmc.ncbi.nlm.nih.gov/articles/PMC9019174/
Pan-Cancer,Alkylating,miR-21,MIR21,Downregulation,Response,"qRT-PCR, RNA-seq",Medium,microRNA,Knockdown sensitizes cells to alkylating agents by upregulating PTEN.,GEO,https://pmc.ncbi.nlm.nih.gov/articles/PMC9019174/
Pan-Cancer,Alkylating,PTEN,PTEN,Upregulation,Response,"RNA-seq, IHC, mutation analysis",Medium,Tumor suppressor,"Upregulated by miR-21 knockdown, sensitizing cells to alkylating agents.","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC9019174/
Pan-Cancer,Alkylating,PARP1/2,"PARP1, PARP2","Mutation, Expression",Response,"RNA-seq, IHC, mutation analysis",Medium,DNA repair enzyme,"Inhibition (e.g., by olaparib) synergizes with alkylating agents.","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC11384948/
Pan-Cancer,Anti-AR,RB1 Loss,RB1,Deletion/Mutation,Non-response,"WES, IHC",Medium,Tumor suppressor,Loss leads to unchecked proliferation and therapy resistance,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC8750084/, https://www.mdpi.com/2072-6694/13/22/5723"
Pan-Cancer,Anti-AR,HSD17B2 Methylation,HSD17B2,Epigenetic Silencing,Non-response,Methylation-specific PCR,Medium,Enzyme,"Silencing increases androgen synthesis, bypassing AR blockade","GEO, TCGA",https://www.spandidos-publications.com/10.3892/wasj.2025.313
Pan-Cancer,Anti-AR,GR Overexpression,NR3C1,Overexpression,Non-response,"RNA-seq, IHC",Medium,Nuclear receptor,Glucocorticoid receptor activation compensates for AR inhibition,"TCGA, GEO","https://www.spandidos-publications.com/10.3892/wasj.2025.313, https://www.mdpi.com/2072-6694/13/22/5723"
Pan-Cancer,Anti-AR,SPOP Mutation,SPOP,Mutation,Non-response,"WES, targeted sequencing",Medium,E3 ubiquitin ligase,"Alters AR degradation, promoting resistance","TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/22/5723
Pan-Cancer,Anti-AR,FOXA1 Mutation,FOXA1,Mutation,Non-response,"WES, targeted sequencing",Medium,Transcription factor,"Alters AR chromatin binding, affecting therapy response","TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/22/5723
Pan-Cancer,Anti-AR,CDK12 Mutation,CDK12,Mutation,Non-response,"WES, targeted sequencing",Medium,Kinase,Associated with genomic instability and poor response,"TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/22/5723
Pan-Cancer,Anti-AR,ETS Fusion,TMPRSS2-ERG,Gene Fusion,Non-response,"FISH, RT-PCR",Medium,Transcription factor,"Fusion drives AR signaling, associated with resistance","TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/22/5723
Pan-Cancer,Anti-AR,Ca 19-9,FUT3/6,Overexpression,Non-response,Serum ELISA,Medium,Glycoprotein,"Marker of aggressive disease, poor response in some cancers","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC5955785/
Pan-Cancer,Anti-AR,EGFR Overexpression,EGFR,Overexpression,Non-response,"IHC, RNA-seq",Medium,Receptor tyrosine kinase,"EGFR pathway activation can bypass AR signaling, conferring resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC5955785/
Pan-Cancer,Anti-CTLA-4,TIM-3,HAVCR2,Amplification,Non-response,"RNA-seq, IHC",Medium,Immune checkpoint,Inhibits T cell responses; associated with resistance,"TCGA, TIMER",https://pmc.ncbi.nlm.nih.gov/articles/PMC11973099/
Pan-Cancer,Anti-CTLA-4,LAG-3,LAG3,Amplification,Non-response,"RNA-seq, IHC",Medium,Immune checkpoint,Suppresses T cell activation; upregulation linked to poor response,"TCGA, TIMER",https://pmc.ncbi.nlm.nih.gov/articles/PMC11973099/
Pan-Cancer,Anti-CTLA-4,TIGIT,TIGIT,Amplification,Non-response,"RNA-seq, IHC",Medium,Immune checkpoint,Inhibits T cell and NK cell activity,"TCGA, TIMER",https://pmc.ncbi.nlm.nih.gov/articles/PMC11973099/
Pan-Cancer,Anti-CTLA-4,HLA Class I,HLA-A/B/C,Deletion/Mutation,Non-response,"WES, RNA-seq",Medium,Antigen-presenting,"Loss impairs antigen presentation, reducing immune detection","TCGA, COSMIC",https://jitc.bmj.com/content/8/Suppl_3/A46
Pan-Cancer,Anti-CTLA-4,IFN-γ Signature,IFNG,Upregulation,Response,RNA-seq,Medium,Cytokine,"Promotes anti-tumor immunity, enhances T cell function","TCGA, GEO",https://jitc.bmj.com/content/8/Suppl_3/A46
Pan-Cancer,Anti-CTLA-4,Treg Cell Frequency,FOXP3,N/A,Non-response,"CyTOF, Flow cytometry",Medium,Transcription factor,High Treg levels suppress anti-tumor immunity,"GEO, TCGA","https://pmc.ncbi.nlm.nih.gov/articles/PMC5840795/, https://pubmed.ncbi.nlm.nih.gov/29510697/"
Pan-Cancer,Anti-CTLA-4,TCR Clonality,N/A,N/A,Response,TCR-seq,Medium,N/A (repertoire),High clonality indicates focused anti-tumor T cell response,"TCGA, GEO",https://jitc.bmj.com/content/8/Suppl_3/A46
Pan-Cancer,Anti-CTLA-4,MHC Class II,HLA-DRA,Deletion/Mutation,Non-response,"WES, RNA-seq",Medium,Antigen-presenting,Loss impairs CD4+ T cell activation,"TCGA, COSMIC",https://jitc.bmj.com/content/8/Suppl_3/A46
Pan-Cancer,Anti-CTLA-4,B2M,B2M,Mutation,Non-response,"WES, RNA-seq",Medium,Antigen-presenting,"Loss disrupts MHC I surface expression, reducing immune recognition","TCGA, COSMIC",https://jitc.bmj.com/content/8/Suppl_3/A46
Pan-Cancer,Anti-EGFR,EGFR amplification,EGFR,Amplification,Response,"Copy number (FISH, NGS)",Medium,Receptor tyrosine kinase,"Increased EGFR signaling, may enhance response","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC2758310/, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Anti-EGFR,PIK3CA mutation,PIK3CA,Mutation,Non-response,"Somatic mutation (NGS, PCR)",Medium,Kinase (enzyme),"Activates PI3K/AKT pathway, confers resistance","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC4974592/, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Anti-EGFR,PTEN loss,PTEN,Deletion/Disruption,Non-response,"IHC, NGS, copy number",Medium,Phosphatase (enzyme),"Loss activates PI3K/AKT, reduces anti-EGFR efficacy","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC4974592/, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Anti-EGFR,HER2 amplification,ERBB2,Amplification,Non-response,"Copy number (FISH, NGS)",Medium,Receptor tyrosine kinase,"Activates alternative growth pathways, confers resistance","TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Anti-EGFR,MET amplification,MET,Amplification,Non-response,"Copy number (FISH, NGS)",Medium,Receptor tyrosine kinase,"Activates bypass signaling, confers resistance","TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Anti-EGFR,EREG expression,EREG,Overexpression,Response,"RNA-seq, qPCR",Medium,Growth factor,High ligand expression predicts better response,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC4974592/
Pan-Cancer,Anti-EGFR,AREG expression,AREG,Overexpression,Response,"RNA-seq, qPCR",Medium,Growth factor,High ligand expression predicts better response,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC4974592/
Pan-Cancer,Anti-PD-1,ISG15,ISG15,Expression,Response,"RNA-seq, IHC",Medium,Ubiquitin-like modifier,"Promotes anti-tumor immunity, associated with better response","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC11985735/
Pan-Cancer,Anti-PD-1,PD-1,PDCD1,Expression,Response,"IHC, RNA-seq",Medium,Receptor,Marker of T cell exhaustion; high levels may indicate immune engagement,"TCGA, GEO",https://www.cancernetwork.com/view/print-biomarkers-for-response-to-anti-pd-1-anti-pd-l1-immune-checkpoint-inhibitors-a-large-meta-analysis
Pan-Cancer,Anti-PD-1,CTLA-4,CTLA4,Expression,Non-response,"IHC, RNA-seq",Medium,Receptor,Immune checkpoint; high expression may indicate resistance,"TCGA, GEO",https://www.cancernetwork.com/view/print-biomarkers-for-response-to-anti-pd-1-anti-pd-l1-immune-checkpoint-inhibitors-a-large-meta-analysis
Pan-Cancer,Anti-PD-1,LAG-3,LAG3,Expression,Non-response,"IHC, RNA-seq",Medium,Receptor,Immune checkpoint; upregulation linked to adaptive resistance,"TCGA, GEO",https://www.cancernetwork.com/view/print-biomarkers-for-response-to-anti-pd-1-anti-pd-l1-immune-checkpoint-inhibitors-a-large-meta-analysis
Pan-Cancer,Anti-PD-1,Beta-2-microglobulin,B2M,"Mutation, Deletion",Non-response,"NGS, PCR",Medium,Structural protein,"Loss impairs antigen presentation, leading to immune escape","TCGA, COSMIC",https://www.cancernetwork.com/view/print-biomarkers-for-response-to-anti-pd-1-anti-pd-l1-immune-checkpoint-inhibitors-a-large-meta-analysis
Pan-Cancer,Anti-PD-1,RAC1,RAC1,Germline Mutation,Non-response (toxicity),Germline sequencing,Medium,GTPase,Associated with increased immune-related adverse events,"TCGA, COSMIC",https://jitc.bmj.com/content/10/2/e003625
Pan-Cancer,Anti-PD-1,Microbiome Signature,N/A,N/A,Response/Non-response,"16S rRNA sequencing, metagenomics",Medium,N/A (Microbial),Certain gut microbiota compositions modulate immune response,N/A,https://www.cancernetwork.com/view/print-biomarkers-for-response-to-anti-pd-1-anti-pd-l1-immune-checkpoint-inhibitors-a-large-meta-analysis
Pan-Cancer,Anti-PD-1,HLA Class I Loss,HLA-A/B/C,"Deletion, Mutation",Non-response,"NGS, PCR",Medium,Antigen-presenting,Loss impairs tumor antigen presentation to T cells,"TCGA, COSMIC",https://www.cancernetwork.com/view/print-biomarkers-for-response-to-anti-pd-1-anti-pd-l1-immune-checkpoint-inhibitors-a-large-meta-analysis
Pan-Cancer,Anti-PD-1,IFN-γ Signature,"IFNG, others",Expression,Response,"RNA-seq, gene expression profiling",Medium,Cytokine,Indicates active immune microenvironment,"TCGA, GEO",https://www.science.org/doi/10.1126/science.aar3593
Pan-Cancer,Anti-VEGF,AKAP12,AKAP12,Overexpression,Non-response,"RNA-seq, qPCR",Medium,Scaffold protein,Upregulated in resistant tumors; linked to poor prognosis and resistance,"GEO, TCGA",https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2022.943006/full
Pan-Cancer,Anti-VEGF,HIF1A,HIF1A,"Overexpression, Mutation",Non-response,"RNA-seq, IHC",Medium,Transcription factor,"Promotes hypoxia response, upregulates VEGF, drives resistance","TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC9667458/, https://www.mdpi.com/1422-0067/14/5/9338"
Pan-Cancer,Anti-VEGF,PDGFB,PDGFB,Overexpression,Non-response,"RNA-seq, IHC",Medium,Growth factor,"Promotes alternative angiogenic pathways, bypassing VEGF blockade","TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC9667458/, https://www.mdpi.com/1422-0067/14/5/9338"
Pan-Cancer,Anti-VEGF,FGF2,FGF2,Overexpression,Non-response,"RNA-seq, IHC",Medium,Growth factor,"Alternative pro-angiogenic factor, mediates resistance","TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC9667458/, https://www.mdpi.com/1422-0067/14/5/9338"
Pan-Cancer,Anti-VEGF,ANGPT2,ANGPT2,Overexpression,Non-response,"RNA-seq, IHC",Medium,Growth factor,"Facilitates angiogenesis, associated with resistance","TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC9667458/, https://www.mdpi.com/1422-0067/14/5/9338"
Pan-Cancer,Anti-VEGF,IL-8,CXCL8,Overexpression,Non-response,"ELISA, RNA-seq",Medium,Cytokine,"Pro-inflammatory, recruits pro-angiogenic myeloid cells, linked to resistance","TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC3178272/, https://www.mdpi.com/1422-0067/14/5/9338"
Pan-Cancer,Anti-VEGF,SDF1,CXCL12,Overexpression,Non-response,"RNA-seq, IHC",Medium,Chemokine,"Recruits bone marrow-derived cells, supports angiogenesis","TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC9667458/, https://www.mdpi.com/1422-0067/14/5/9338"
Pan-Cancer,Anti-VEGF,EMT markers,Various,Overexpression,Non-response,"RNA-seq, IHC",Medium,Various,"Epithelial-mesenchymal transition, increases aggressiveness and resistance","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC3178272/
Pan-Cancer,Anti-VEGF,TGF-β1,TGFB1,Overexpression,Non-response,"RNA-seq, IHC",Medium,Cytokine,"Induces EMT, promotes resistance to anti-VEGF therapy","TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC3178272/, https://www.mdpi.com/1422-0067/14/5/9338"
Pan-Cancer,Anti-VEGF,PlGF,PGF,Overexpression,Non-response,"RNA-seq, IHC",Medium,Growth factor,"Alternative angiogenic pathway, mediates resistance","TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC9667458/, https://www.mdpi.com/1422-0067/14/5/9338"
Pan-Cancer,Anti-VEGF,MMP9,MMP9,Overexpression,Non-response,"RNA-seq, IHC",Medium,Enzyme (protease),"Matrix remodeling, promotes angiogenesis and resistance","TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC9667458/, https://www.mdpi.com/1422-0067/14/5/9338"
Pan-Cancer,Anti-VEGF,EGFR,EGFR,"Amplification, Mutation",Non-response,"PCR, IHC, RNA-seq",Medium,Receptor tyrosine kinase,"Activates alternative angiogenic pathways, linked to resistance","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC9667458/, https://www.mdpi.com/1422-0067/14/5/9338"
Pan-Cancer,Anti-VEGF,PTEN,PTEN,"Deletion, Mutation",Non-response,"PCR, Sequencing",Medium,Phosphatase (enzyme),"Loss leads to PI3K/AKT activation, promotes angiogenesis and resistance","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC9667458/, https://www.mdpi.com/1422-0067/14/5/9338"
Pan-Cancer,Aromatase inhibitor,RRM2,RRM2,Amplification,Non-response,"RNA-seq, Copy number",Medium,Enzyme,"Promotes DNA synthesis and cell proliferation, associated with AI resistance","TCGA, GEO",https://sciety.org/articles/activity/10.21203/rs.3.rs-6183643/v1
Pan-Cancer,Aromatase inhibitor,ABI3,ABI3,Downregulation,Non-response,RNA-seq,Medium,Adapter protein,"Loss linked to metastasis and poor prognosis in pan-cancer, including breast","TCGA, GEO",https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1277830/full
Pan-Cancer,Aromatase inhibitor,PIK3CA Mutation,PIK3CA,Mutation,Non-response,Somatic mutation analysis,Medium,Enzyme,"Activates PI3K pathway, promoting survival and AI resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10328947/
Pan-Cancer,Aromatase inhibitor,GATA3,GATA3,Mutation,Response,Somatic mutation analysis,Medium,Transcription factor,"GATA3 mutations often retain luminal phenotype, associated with better AI response","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10328947/
Pan-Cancer,Aromatase inhibitor,FGFR1,FGFR1,Amplification,Non-response,"Copy number, FISH",Medium,Receptor tyrosine kinase,"FGFR1 amplification drives estrogen-independent growth, reducing AI efficacy","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10328947/
Pan-Cancer,Aromatase inhibitor,CCND1,CCND1,Amplification,Non-response,"Copy number, FISH",Medium,Cell cycle regulator,"Promotes cell cycle progression, associated with AI resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10328947/
Pan-Cancer,Aromatase inhibitor,BCL2,BCL2,Overexpression,Response,"IHC, RNA-seq",Medium,Anti-apoptotic protein,High BCL2 expression linked to luminal phenotype and better AI response,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10328947/
Pan-Cancer,Aromatase inhibitor,PR (Progesterone Receptor),PGR,Downregulation,Non-response,"IHC, RNA-seq",Medium,Nuclear receptor,Loss of PR indicates endocrine resistance,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10328947/
Pan-Cancer,Aromatase inhibitor,CDK4/6,"CDK4, CDK6",Amplification,Non-response,"Copy number, RNA-seq",Medium,Cell cycle kinase,"Overactivity promotes proliferation, associated with AI resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10328947/
Pan-Cancer,Chemotherapy,CDKN2A Loss,CDKN2A,Deletion,Non-response,"NGS, FISH",Medium,Tumor suppressor,"Loss leads to cell cycle dysregulation, chemo resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/
Pan-Cancer,Chemotherapy,SMAD4 Loss,SMAD4,Deletion/Mutation,Non-response,"NGS, IHC",Medium,Transcription factor,Loss associated with poor response in pancreatic and other cancers,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/
Pan-Cancer,Chemotherapy,ATM Mutation,ATM,Mutation,Response,"NGS, PCR",Medium,Kinase (enzyme),DNA repair defect increases chemo sensitivity,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/
Pan-Cancer,Chemotherapy,ARID1A Mutation,ARID1A,Mutation,Non-response,"NGS, PCR",Medium,Chromatin remodeler,"Loss impairs DNA repair, may affect chemo response","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/
Pan-Cancer,Chemotherapy,CD3+ T-cell Infiltration,N/A,N/A,Response,"IHC, mRNA-seq",Medium,Immune cell marker,High infiltration predicts better chemo response in some cancers,"TCGA, GEO",https://www.precisionmedicineonline.com/precision-oncology/immune-biomarkers-could-predict-first-line-chemo-response-pancreatic-cancer
Pan-Cancer,Chemotherapy,CD8+ T-cell Infiltration,N/A,N/A,Response,"IHC, mRNA-seq",Medium,Immune cell marker,Cytotoxic T-cell presence linked to improved response,"TCGA, GEO",https://www.precisionmedicineonline.com/precision-oncology/immune-biomarkers-could-predict-first-line-chemo-response-pancreatic-cancer
Pan-Cancer,Chemotherapy,ERCC1 Expression,ERCC1,Amplification,Non-response,"IHC, qPCR",Medium,DNA repair enzyme,High expression linked to platinum resistance,"TCGA, GEO, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Chemotherapy,BCL2 Expression,BCL2,Amplification,Non-response,"IHC, qPCR",Medium,Anti-apoptotic,Overexpression confers resistance to apoptosis-inducing chemo,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Chemotherapy,TUBB3 Expression,TUBB3,Amplification,Non-response,"IHC, qPCR",Medium,Structural protein,High expression linked to taxane resistance,"TCGA, GEO",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Chemotherapy,TOP2A Amplification,TOP2A,Amplification,Response,"FISH, qPCR",Medium,Enzyme (topoisomerase),Amplification predicts anthracycline sensitivity,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Chemotherapy,CDKN2A,CDKN2A,Deletion/Mutation,Non-response,"NGS, PCR",Medium,Tumor suppressor,Cell cycle regulator; loss linked to poor chemo response,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Chemotherapy,SMAD4,SMAD4,Mutation/Deletion,Non-response,"NGS, PCR",Medium,Transcription factor,TGF-β pathway; loss associated with chemoresistance in pancreatic cancer,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Chemotherapy,ARID1A,ARID1A,Mutation,Non-response,"NGS, PCR",Medium,Chromatin remodeler,Loss linked to resistance to DNA-damaging agents,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Chemotherapy,ATM,ATM,Mutation,Response,"NGS, PCR",Medium,DNA repair kinase,Mutations may sensitize to DNA-damaging chemo,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Chemotherapy,CD3+ T cells,CD3E,N/A,Response,"IHC, mRNA-seq",Medium,Immune receptor,T-cell infiltration predicts better chemo response,"TCGA, GEO","https://www.precisionmedicineonline.com/precision-oncology/immune-biomarkers-could-predict-first-line-chemo-response-pancreatic-cancer, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Chemotherapy,CD8+ T cells,CD8A,N/A,Response,"IHC, mRNA-seq",Medium,Immune receptor,Cytotoxic T-cell presence linked to improved chemo response,"TCGA, GEO","https://www.precisionmedicineonline.com/precision-oncology/immune-biomarkers-could-predict-first-line-chemo-response-pancreatic-cancer, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Chemotherapy,TOP2A,TOP2A,Amplification,Response,"FISH, qPCR",Medium,DNA topoisomerase,Amplification predicts response to anthracyclines,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Chemotherapy,TUBB3,TUBB3,Overexpression,Non-response,"IHC, qPCR",Medium,Structural protein,High expression linked to taxane resistance,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Chemotherapy,CDKN2A,CDKN2A,Deletion/Mutation,Non-response,Somatic mutation/deletion (NGS),Medium,Tumor suppressor,"Loss leads to cell cycle dysregulation, chemo resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/
Pan-Cancer,Chemotherapy,SMAD4,SMAD4,Mutation/Deletion,Non-response,Somatic mutation/deletion (NGS),Medium,Signal transducer,"Loss impairs TGF-β signaling, linked to poor chemo response","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/
Pan-Cancer,Chemotherapy,ATM,ATM,Mutation,Response,Somatic mutation (NGS),Medium,DNA repair enzyme,Deficiency may sensitize to DNA-damaging agents,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/
Pan-Cancer,Chemotherapy,ARID1A,ARID1A,Mutation,Non-response,Somatic mutation (NGS),Medium,Chromatin remodeler,Loss linked to chemo resistance in some cancers,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/
Pan-Cancer,Chemotherapy,CD3+ T cells,N/A,N/A,Response,"IHC, mRNA-seq",Medium,Immune cell marker,High infiltration predicts better chemo response,"TCGA, GEO",https://www.precisionmedicineonline.com/precision-oncology/immune-biomarkers-could-predict-first-line-chemo-response-pancreatic-cancer
Pan-Cancer,Chemotherapy,CD8+ T cells,N/A,N/A,Response,"IHC, mRNA-seq",Medium,Immune cell marker,Cytotoxic T cell presence linked to improved chemo response,"TCGA, GEO",https://www.precisionmedicineonline.com/precision-oncology/immune-biomarkers-could-predict-first-line-chemo-response-pancreatic-cancer
Pan-Cancer,Chemotherapy,BCL2,BCL2,Overexpression,Non-response,"IHC, RNA-seq",Medium,Anti-apoptotic protein,Overexpression inhibits chemo-induced apoptosis,"TCGA, GEO",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Chemotherapy,TOP2A,TOP2A,Amplification,Response,"FISH, RNA-seq",Medium,Enzyme (topoisomerase),Amplification predicts response to anthracyclines,"TCGA, GEO, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Chemotherapy,TUBB3,TUBB3,Overexpression,Non-response,"IHC, RNA-seq",Medium,Structural protein,High expression linked to taxane resistance,"TCGA, GEO",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Folinic acid,Folate Receptor Alpha (FRα),FOLR1,Overexpression,Response,"IHC, RNA-seq",Medium,Receptor,"High FRα enhances folate/FA uptake, improving drug delivery","TCGA, GEO",https://journals.sagepub.com/doi/10.1177/03000605231223064
Pan-Cancer,Folinic acid,Methylenetetrahydrofolate Reductase (MTHFR),MTHFR,Mutation,Non-response,"PCR, Genotyping",Medium,Enzyme,"MTHFR polymorphisms affect folate metabolism, altering FA therapy efficacy","TCGA, COSMIC",https://journals.sagepub.com/doi/10.1177/03000605231223064
Pan-Cancer,Folinic acid,Excision Repair Cross-Complementation Group 1 (ERCC1),ERCC1,Overexpression,Non-response,"IHC, RNA-seq",Medium,DNA repair enzyme,High ERCC1 linked to resistance to platinum/FA-based regimens,"TCGA, COSMIC",https://www.oncotarget.com/article/27872/text/
Pan-Cancer,Folinic acid,ATP-Binding Cassette Subfamily B Member 1 (ABCB1),ABCB1,"Amplification, Overexpression",Non-response,"RNA-seq, IHC",Medium,Transporter,"ABCB1 overexpression increases drug efflux, reducing FA/5-FU efficacy","TCGA, COSMIC",https://www.oncotarget.com/article/27872/text/
Pan-Cancer,Folinic acid,p53,TP53,Mutation,Non-response,"PCR, NGS, IHC",Medium,Tumor suppressor,TP53 mutations linked to poor response to FA/5-FU-based regimens,"TCGA, COSMIC",https://www.oncotarget.com/article/27872/text/
Pan-Cancer,Folinic acid,Glutathione S-Transferase Pi 1 (GSTP1),GSTP1,"Mutation, Overexpression",Non-response,"PCR, IHC, RNA-seq",Medium,Enzyme,GSTP1 overexpression confers resistance to FA/5-FU by detoxifying drugs,"TCGA, COSMIC",https://www.oncotarget.com/article/27872/text/
Pan-Cancer,Folinic acid,Thymidine Phosphorylase (TYMP),TYMP,Overexpression,Response,"IHC, RNA-seq",Medium,Enzyme,"High TYMP enhances 5-FU activation, improving FA/5-FU efficacy","TCGA, COSMIC",https://www.oncotarget.com/article/27872/text/
Pan-Cancer,Hormonal therapy,AR,AR,"Mutation, Amplif.",Non-response,"IHC, RNA-seq, PCR",Medium,Nuclear receptor,AR signaling can drive resistance in some hormone therapies,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,FGFR1,FGFR1,Amplification,Non-response,"FISH, PCR, NGS",Medium,Receptor tyrosine kinase,Amplification linked to endocrine resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,CCND1,CCND1,Amplification,Non-response,"FISH, PCR, NGS",Medium,Cell cycle regulator,Amplification linked to resistance to endocrine therapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,ESR1 Fusion,ESR1,Gene fusion,Non-response,"NGS, RNA-seq",Medium,Nuclear receptor,"Fusions drive ligand-independent ER activity, causing resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,AKT1,AKT1,Mutation,Non-response,"NGS, PCR",Medium,Enzyme (kinase),Activating mutations linked to resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,PTEN,PTEN,"Deletion, Mutation",Non-response,"NGS, PCR",Medium,Tumor suppressor,Loss leads to PI3K pathway activation and resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,GATA3,GATA3,Mutation,Response,"NGS, PCR",Medium,Transcription factor,Mutations may predict better response to hormonal therapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,RB1,RB1,"Mutation, Deletion",Non-response,"NGS, PCR",Medium,Tumor suppressor,Loss confers resistance to CDK4/6 inhibitors in HR+ cancers,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,BRCA1/2,BRCA1/2,"Mutation, Deletion",Response,"NGS, PCR",Medium,DNA repair enzyme,"Deficiency increases sensitivity to PARP inhibitors, affects hormonal response","TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Hormonal therapy,PTEN Loss,PTEN,"Deletion, Mutation",Non-response,"IHC, NGS",Medium,Phosphatase,"Loss leads to PI3K pathway activation, resistance to hormonal therapy","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,FGFR1 Amplification,FGFR1,Amplification,Non-response,"FISH, NGS",Medium,Receptor tyrosine kinase,Amplification associated with endocrine resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,CCND1 Amplification,CCND1,Amplification,Non-response,"FISH, NGS",Medium,Cell cycle regulator,"Drives cell cycle progression, linked to resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,AR (Androgen Receptor),AR,Overexpression,Non-response,"IHC, RNA-seq",Medium,Nuclear receptor,"AR signaling can bypass ER pathway, leading to resistance","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,BCL2,BCL2,Overexpression,Response,"IHC, RNA-seq",Medium,Anti-apoptotic,High BCL2 linked to better prognosis and response,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,CDK4/6 Pathway,CDK4/6,Amplification,Non-response,"NGS, FISH",Medium,Kinase,"Activation confers resistance, CDK4/6 inhibitors can restore sensitivity","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,TP53 Mutation,TP53,Mutation,Non-response,"NGS, PCR",Medium,Tumor suppressor,Mutations linked to poor response to hormonal therapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Immunotherapy,CTLA-4,CTLA4,"Mutation, Overexpression",Response/Non-response,"IHC, RNA-seq, NGS",Medium,Immune checkpoint receptor,Regulates T-cell activation; mutations may affect ICI efficacy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/
Pan-Cancer,Immunotherapy,LAG-3,LAG3,Overexpression,Non-response,"IHC, RNA-seq",Medium,Immune checkpoint receptor,Inhibits T-cell function; high expression linked to resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/
Pan-Cancer,Immunotherapy,IDO1,IDO1,Overexpression,Non-response,"IHC, RNA-seq",Medium,Enzyme,Suppresses T-cell function via tryptophan metabolism,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/
Pan-Cancer,Immunotherapy,STK11 (LKB1),STK11,"Mutation, Deletion",Non-response,"NGS, PCR",Medium,Kinase,Loss impairs immune cell infiltration and response to ICIs,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/
Pan-Cancer,Immunotherapy,ALK,ALK,Rearrangement,Non-response,"FISH, NGS",Medium,Receptor tyrosine kinase,ALK fusions associated with poor response to ICIs,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/
Pan-Cancer,Immunotherapy,KRAS,KRAS,Mutation,Response/Non-response,"NGS, PCR",Medium,GTPase,Certain KRAS mutations may enhance or reduce ICI efficacy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/
Pan-Cancer,Immunotherapy,TGF-β,TGFB1,Overexpression,Non-response,"IHC, RNA-seq",Medium,Cytokine,Promotes immunosuppressive tumor microenvironment,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10547938/
Pan-Cancer,Multikinase inhibitor,MET Amplification,MET,Amplification,Response,"Copy number (FISH, NGS)",Medium,Receptor tyrosine kinase,Promotes proliferation; predicts response to MET inhibitors,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Multikinase inhibitor,FGFR Alteration,FGFR1-4,Mutation/Fusion,Response,Somatic Mutation/Fusion (NGS),Medium,Receptor tyrosine kinase,Drives proliferation; predicts response to FGFR inhibitors,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Multikinase inhibitor,PDGFRA Mutation,PDGFRA,Mutation,Response,"Somatic Mutation (PCR, NGS)",Medium,Receptor tyrosine kinase,Activates signaling; predicts response to PDGFRA inhibitors,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Multikinase inhibitor,VEGFA Overexpression,VEGFA,Overexpression,Response,"RNA-seq, IHC",Medium,Growth factor,Promotes angiogenesis; predicts response to anti-angiogenic therapies,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC9169228/
Pan-Cancer,Platinum,PALB2,PALB2,Mutation,Response,Somatic/germline sequencing,Medium,DNA repair partner,Works with BRCA2 in HR; loss increases platinum sensitivity,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC8928350/, https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full"
Pan-Cancer,Platinum,ATM,ATM,Mutation,Response,Somatic/germline sequencing,Medium,Kinase,"DDR kinase; loss impairs DNA repair, increasing platinum response","TCGA, COSMIC",https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full
Pan-Cancer,Platinum,CHEK2,CHEK2,Mutation,Response,Somatic/germline sequencing,Medium,Kinase,DDR checkpoint kinase; loss may sensitize to platinum,"TCGA, COSMIC",https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full
Pan-Cancer,Platinum,RAD51,RAD51,Mutation,Response,Somatic/germline sequencing,Medium,DNA repair enzyme,Central to HR; loss increases platinum sensitivity,"TCGA, COSMIC",https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full
Pan-Cancer,Platinum,ERCC4,ERCC4,Mutation,Response,Somatic/germline sequencing,Medium,DNA repair enzyme,Nucleotide excision repair; loss may sensitize to platinum,"TCGA, COSMIC",https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full
Pan-Cancer,Platinum,FANCA,FANCA,Mutation,Response,Somatic/germline sequencing,Medium,DNA repair enzyme,Fanconi anemia pathway; loss increases platinum sensitivity,"TCGA, COSMIC",https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full
Pan-Cancer,Platinum,MLH1,MLH1,"Mutation, Methylation",Response,"Methylation-specific PCR, sequencing",Medium,DNA mismatch repair,"Deficiency impairs DNA repair, increasing platinum sensitivity","TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Platinum,MSH2,MSH2,Mutation,Response,Somatic/germline sequencing,Medium,DNA mismatch repair,"Loss impairs repair, increasing platinum sensitivity","TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Platinum,BCL2,BCL2,Overexpression,Non-response,"RNA-seq, IHC",Medium,Anti-apoptotic protein,"Overexpression inhibits apoptosis, conferring platinum resistance","TCGA, GEO",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Platinum,CCNE1,CCNE1,Amplification,Non-response,Copy number analysis,Medium,Cell cycle regulator,"Amplification drives cell cycle, associated with platinum resistance","TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Platinum,SLFN11,SLFN11,Expression loss,Non-response,"RNA-seq, IHC",Medium,DNA/RNA helicase,"Loss of expression linked to resistance to DNA-damaging agents, including platinum","TCGA, GEO",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Platinum,PALB2,PALB2,Mutation,Response,"Somatic/germline mutation testing (NGS, PCR)",Medium,DNA repair scaffold,Facilitates BRCA2 function in DNA repair; loss increases platinum sensitivity,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC8928350/, https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full"
Pan-Cancer,Platinum,ATM,ATM,Mutation,Response,"Somatic/germline mutation testing (NGS, PCR)",Medium,Kinase (DDR),"Senses DNA damage; loss impairs repair, increasing platinum sensitivity","TCGA, COSMIC",https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full
Pan-Cancer,Platinum,CHEK2,CHEK2,Mutation,Response,"Somatic/germline mutation testing (NGS, PCR)",Medium,Kinase (DDR),"DNA damage checkpoint; loss impairs repair, increasing platinum sensitivity","TCGA, COSMIC",https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full
Pan-Cancer,Platinum,RAD51,RAD51,"Mutation, Disruption",Response,Somatic mutation testing (NGS),Medium,DNA repair enzyme,Central to homologous recombination; loss increases platinum sensitivity,"TCGA, COSMIC",https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full
Pan-Cancer,Platinum,MLH1,MLH1,"Mutation, Methylation",Response,"Methylation-specific PCR, IHC, NGS",Medium,DNA mismatch repair,"Deficiency increases DNA damage, sensitizing to platinum","TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Platinum,FANCA,FANCA,Mutation,Response,"Somatic/germline mutation testing (NGS, PCR)",Medium,DNA repair enzyme,Fanconi anemia pathway; loss increases platinum sensitivity,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC8928350/, https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full"
Pan-Cancer,Platinum,TP53,TP53,Mutation,Non-response,Somatic mutation testing (NGS),Medium,Tumor suppressor,"Loss impairs apoptosis, may confer resistance to DNA-damaging agents","TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Platinum,MSH2,MSH2,"Mutation, Deletion",Response,"Somatic/germline mutation testing (NGS, PCR)",Medium,DNA mismatch repair,"Deficiency increases DNA damage, sensitizing to platinum","TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Platinum,SLFN11,SLFN11,Low expression,Non-response,"RNA-seq, qPCR, IHC",Medium,DNA/RNA helicase,"Low expression linked to resistance to DNA-damaging agents, including platinum","TCGA, GEO",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Pyrimidine (ant)agonist,Orotate Phosphoribosyltransferase,UMPS,"Mutation, Deletion",Response,"RNA-seq, PCR",Medium,Enzyme,Activates 5-FU prodrug; loss reduces efficacy,"TCGA, COSMIC",https://research.rug.nl/files/2914175/thesis.pdf
Pan-Cancer,Pyrimidine (ant)agonist,Methylenetetrahydrofolate Reductase,MTHFR,Polymorphism,"Non-response, Toxicity","Germline SNP, PCR",Medium,Enzyme,"Alters folate metabolism, affecting 5-FU efficacy and toxicity","PharmGKB, TCGA",https://research.rug.nl/files/2914175/thesis.pdf
Pan-Cancer,Pyrimidine (ant)agonist,Thymidine Phosphorylase,TYMP,Overexpression,Response,"RNA-seq, IHC",Medium,Enzyme,Activates capecitabine and 5-FU; higher levels improve drug activation,TCGA,https://research.rug.nl/files/2914175/thesis.pdf
Pan-Cancer,Pyrimidine (ant)agonist,Dihydroorotate Dehydrogenase,DHODH,"Mutation, Overexpression",Non-response,"RNA-seq, PCR",Medium,Enzyme,Key in de novo pyrimidine synthesis; inhibition sensitizes tumors,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8194085/
Pan-Cancer,Pyrimidine (ant)agonist,ABCG2 (BCRP),ABCG2,Overexpression,Non-response,"RNA-seq, IHC, PCR",Medium,Transporter,"Effluxes pyrimidine antagonists, mediates multidrug resistance","TCGA, COSMIC",https://www.uspharmacist.com/article/pharmacogenomic-biomarkers-for-toxicities-associated-with-chemotherapy
Pan-Cancer,Pyrimidine (ant)agonist,P-glycoprotein (MDR1),ABCB1,Overexpression,Non-response,"RNA-seq, IHC, PCR",Medium,Transporter,"Pumps out drugs, including pyrimidine antagonists, leading to resistance","TCGA, COSMIC",https://www.uspharmacist.com/article/pharmacogenomic-biomarkers-for-toxicities-associated-with-chemotherapy
Pan-Cancer,Pyrimidine (ant)agonist,MRP1 (ABCC1),ABCC1,Overexpression,Non-response,"RNA-seq, IHC, PCR",Medium,Transporter,"Multidrug resistance protein, effluxes pyrimidine antagonists","TCGA, COSMIC",https://www.uspharmacist.com/article/pharmacogenomic-biomarkers-for-toxicities-associated-with-chemotherapy
Pan-Cancer,Targeted therapy,MET amplification,MET,Amplification,Response,"FISH, NGS",Medium,Receptor tyrosine kinase,Promotes proliferation; predicts response to MET inhibitors,"TCGA, COSMIC",https://pubmed.ncbi.nlm.nih.gov/34373099/
Pan-Cancer,Targeted therapy,PIK3CA mutation,PIK3CA,Mutation,Response,"NGS, PCR",Medium,Kinase,Activates PI3K pathway; predicts response to PI3K inhibitors,"TCGA, COSMIC",https://pubmed.ncbi.nlm.nih.gov/34373099/
Pan-Cancer,Targeted therapy,PTEN loss,PTEN,Deletion/Mutation,Non-response,"IHC, NGS",Medium,Phosphatase,Loss activates PI3K/AKT; associated with resistance to targeted therapies,"TCGA, COSMIC",https://pubmed.ncbi.nlm.nih.gov/34373099/
Pan-Cancer,Targeted therapy,FGFR2/3 fusion,FGFR2/3,Gene rearrangement,Response,"NGS, FISH",Medium,Receptor tyrosine kinase,Constitutive kinase activity; predicts response to FGFR inhibitors,"TCGA, COSMIC",https://pubmed.ncbi.nlm.nih.gov/34373099/
Pan-Cancer,Taxane,MAPT (Tau),MAPT,Expression,Non-response,"IHC, RNA-seq",Medium,Microtubule-associated,"High expression stabilizes microtubules, reducing taxane efficacy","TCGA, GEO",https://www.mdpi.com/2072-6694/13/16/4055
Pan-Cancer,Taxane,ERCC1,ERCC1,Expression,Non-response,"RNA-seq, IHC",Medium,DNA repair enzyme,High expression linked to resistance via enhanced DNA repair,"TCGA, GEO",https://www.mdpi.com/2072-6694/13/16/4055
Pan-Cancer,Taxane,CYP3A4,CYP3A4,Expression,Non-response,"RNA-seq, PCR",Medium,Enzyme (P450),"Metabolizes taxanes, reducing drug efficacy","TCGA, GEO",https://www.mdpi.com/2072-6694/13/16/4055
Pan-Cancer,Taxane,STMN1 (Stathmin),STMN1,Expression,Non-response,"IHC, RNA-seq",Medium,Microtubule regulator,"Overexpression destabilizes microtubules, conferring resistance","TCGA, GEO",https://www.mdpi.com/2072-6694/13/16/4055
Pan-Cancer,Taxane,BCL2,BCL2,Expression,Non-response,"IHC, RNA-seq",Medium,Anti-apoptotic protein,"High expression inhibits apoptosis, reducing taxane-induced cell death","TCGA, GEO",https://www.mdpi.com/2072-6694/13/16/4055
Pan-Cancer,Taxane,AR (Androgen Receptor),AR,Amplification,Non-response,"IHC, PCR",Medium,Nuclear receptor,Overexpression linked to taxane resistance in prostate cancer,"TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/16/4055
Pan-Cancer,Taxane,PIK3CA,PIK3CA,Mutation,Non-response,"Somatic Mutation, PCR",Medium,Kinase,Activating mutations linked to resistance via PI3K pathway,"TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/16/4055
Pan-Cancer,Taxane,PTEN,PTEN,Deletion,Non-response,"Somatic Mutation, PCR",Medium,Tumor suppressor,Loss leads to PI3K pathway activation and taxane resistance,"TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/16/4055
Pan-Cancer,Taxane,FOXM1,FOXM1,Expression,Non-response,"RNA-seq, IHC",Medium,Transcription factor,Overexpression promotes cell cycle progression and resistance,"TCGA, GEO",https://www.mdpi.com/2072-6694/13/16/4055
Pancreas PAAD,Chemotherapy,CA125,MUC16,Overexpression,Response,Serum ELISA,Medium,Glycoprotein,Tumor marker; decrease may indicate response,"TCGA, GEO",https://tcr.amegroups.org/article/view/18840/14924
Pancreas PAAD,Chemotherapy,ctDNA (TP53),TP53,Mutation,Non-response,"Liquid biopsy, PCR, NGS",Medium,Transcription factor,Mutant ctDNA associated with resistance,"TCGA, COSMIC",https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full
Pancreas PAAD,Chemotherapy,ctDNA (SMAD4),SMAD4,Mutation/Deletion,Non-response,"Liquid biopsy, PCR, NGS",Medium,Signal transducer,Loss linked to poor chemo response,"TCGA, COSMIC",https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full
Pancreas PAAD,Chemotherapy,CD3+ T cells,CD3E,Infiltration,Response,"IHC, mRNA-seq",Medium,Immune receptor,High infiltration predicts better chemo response,"TCGA, GEO",https://www.precisionmedicineonline.com/precision-oncology/immune-biomarkers-could-predict-first-line-chemo-response-pancreatic-cancer
Pancreas PAAD,Chemotherapy,CD8+ T cells,CD8A,Infiltration,Response,"IHC, mRNA-seq",Medium,Immune receptor,High infiltration linked to improved response,"TCGA, GEO",https://www.precisionmedicineonline.com/precision-oncology/immune-biomarkers-could-predict-first-line-chemo-response-pancreatic-cancer
Pancreas PAAD,Chemotherapy,MUC1,MUC1,Overexpression,Non-response,"IHC, RNA-seq",Medium,Glycoprotein,Overexpression linked to chemoresistance,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10293428/
Pancreas PAAD,Chemotherapy,RRM1,RRM1,Overexpression,Non-response,"IHC, RNA-seq",Medium,Enzyme,High levels linked to gemcitabine resistance,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10293428/
Pancreas PAAD,Chemotherapy,SPARC,SPARC,Overexpression,Response,"IHC, RNA-seq",Medium,Glycoprotein,High stromal SPARC may predict response to nab-paclitaxel,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10293428/
Pancreas PAAD,Chemotherapy,GATA6,GATA6,Overexpression,Response,"RNA-seq, IHC",Medium,Transcription factor,Classical subtype (GATA6 high) more chemo-sensitive,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10293428/
Pancreas PAAD,Folinic acid,hENT1,SLC29A1,Expression,Response,"IHC, RNA-seq",Medium,Transporter,"Nucleoside transporter, predicts response to nucleoside analogs","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6478006/
Pancreas PAAD,Folinic acid,hCNT3,SLC28A3,Expression,Response,"IHC, RNA-seq",Medium,Transporter,"Nucleoside transporter, higher expression linked to better survival","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6478006/
Pancreas PAAD,Folinic acid,CES2,CES2,Expression,Response,"IHC, RNA-seq",Medium,Enzyme,"Carboxylesterase, activates irinotecan, higher expression linked to better OS","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC6478006/
Pancreas PAAD,Folinic acid,Basal-like Subtype,Multiple,Expression,Non-response,"RNA-seq, Organoid profiling",Medium,Transcriptional,Basal-like tumors show resistance to FOLFIRINOX/5-FU,TCGA,https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full
Pancreas PAAD,Folinic acid,Neutropenia,N/A,Treatment effect,Response,CBC (blood count),Medium,N/A,Development of neutropenia during therapy linked to better outcomes,Clinical datasets,https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.762
Pancreas PAAD,Folinic acid,FFX-ΔGEP,Multiple,Expression,Non-response,Circulating RNA (PCR),Medium,Multigene signature,Early circulating multigene biomarker predicts lack of FOLFIRINOX response,"GEO, TCGA",https://pubmed.ncbi.nlm.nih.gov/36652890/
Pancreas PAAD,Folinic acid,SMAD4 Loss,SMAD4,Deletion,Non-response,"IHC, NGS",Medium,Signal transducer,Loss associated with poor prognosis and resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6478006/
Pancreas PAAD,Folinic acid,BRCA1/2 Mutation,BRCA1/2,Mutation,Response,"PCR, NGS",Medium,DNA repair enzyme,Deficiency may sensitize to platinum-based therapies in FOLFIRINOX,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6478006/
Pancreas PAAD,Folinic acid,ERCC1,ERCC1,Expression,Non-response,"IHC, RNA-seq",Medium,DNA repair enzyme,High expression linked to resistance to platinum agents,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC6478006/
Prostate,Anti-AR,AR T877A Mutation,AR,Mutation,Non-response,"NGS, Sanger sequencing",Medium,Nuclear receptor,"Alters ligand specificity, enabling AR activation by other steroids","COSMIC, TCGA",https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1542811/full
Prostate,Anti-AR,TP53 Mutation,TP53,Mutation,Non-response,"NGS, Sanger sequencing",Medium,Transcription factor,"Loss of tumor suppressor function, associated with aggressive disease","TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/22/5723
Prostate,Anti-AR,RB1 Loss,RB1,Deletion/Mutation,Non-response,"IHC, NGS",Medium,Tumor suppressor,Loss promotes lineage plasticity and AR-independence,"TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/22/5723
Prostate,Anti-AR,MYC Overexpression,MYC,Amplification,Non-response,"RNA-seq, IHC",Medium,Transcription factor,"Drives proliferation, associated with AR therapy resistance","TCGA, GEO",https://www.jci.org/articles/view/165357
Prostate,Anti-AR,SPOP Mutation,SPOP,Mutation,Response,"NGS, Sanger sequencing",Medium,E3 ubiquitin ligase,Sensitizes to AR-targeted therapy by affecting AR degradation,"TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/22/5723
Prostate,Anti-AR,TMPRSS2-ERG Fusion,"TMPRSS2, ERG",Gene fusion,Variable,"FISH, RT-PCR",Medium,Transcription factor,Alters AR signaling; impact on response is context-dependent,"TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/22/5723
Prostate,Anti-AR,AKT1 Activation,AKT1,Mutation/Activation,Non-response,"IHC, NGS",Medium,Kinase,Promotes survival pathways independent of AR,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC9319825/
Prostate,Chemotherapy,cfDNA,Multiple,Somatic Mutations,Non-response,Blood-based NGS,Medium,N/A (DNA marker),High cfDNA levels linked to poor prognosis and therapy resistance,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC5524249/
Prostate,Chemotherapy,ALDH1A1,ALDH1A1,Overexpression,Non-response,"IHC, RNA-seq",Medium,Enzyme,"Cancer stem cell marker, linked to chemoresistance","GEO, TCGA","https://pmc.ncbi.nlm.nih.gov/articles/PMC10649216/, https://www.mdpi.com/2072-6694/13/22/5723"
Prostate,Chemotherapy,VEGF,VEGFA,Overexpression,Non-response,"ELISA, IHC",Medium,Growth factor,"Promotes angiogenesis, linked to resistance to chemotherapy","GEO, TCGA",https://journals.sagepub.com/doi/10.1177/15330338241290029
Prostate,Chemotherapy,IL-6,IL6,Overexpression,Non-response,"ELISA, IHC",Medium,Cytokine,"Inflammatory mediator, high levels linked to poor chemo response","GEO, TCGA",https://journals.sagepub.com/doi/10.1177/15330338241290029
Prostate,Chemotherapy,TNF-α,TNF,Overexpression,Non-response,"ELISA, IHC",Medium,Cytokine,"Pro-inflammatory, associated with aggressive and resistant disease","GEO, TCGA",https://journals.sagepub.com/doi/10.1177/15330338241290029
Prostate,Chemotherapy,Osteopontin,SPP1,Overexpression,Non-response,"ELISA, IHC",Medium,Glycoprotein,"Promotes metastasis, linked to chemoresistance","GEO, TCGA",https://journals.sagepub.com/doi/10.1177/15330338241290029
Prostate,Hormonal therapy,ETS-related gene fusion (ERG),ERG,Gene fusion,Non-response,"FISH, RT-PCR, NGS",Medium,Transcription factor,ERG fusion status associated with resistance to some hormonal therapies.,"TCGA, COSMIC",https://www.mdpi.com/1718-7729/29/7/400
Prostate,Hormonal therapy,SPOP Mutation,SPOP,Mutation,Response,"NGS, PCR",Medium,E3 ubiquitin ligase,SPOP mutations sensitize tumors to AR-targeted therapy.,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8616385/
Prostate,Hormonal therapy,BRCA2 Mutation,BRCA2,Mutation,Non-response,"NGS, PCR",Medium,DNA repair enzyme,BRCA2 mutations associated with aggressive disease and poor hormonal response.,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8616385/
Prostate,Hormonal therapy,CHD1 Deletion,CHD1,Deletion,Response,"FISH, NGS",Medium,Chromatin remodeler,CHD1 loss may sensitize to AR-targeted therapy.,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8616385/
Prostate,Hormonal therapy,FOXA1 Mutation,FOXA1,Mutation,Non-response,"NGS, PCR",Medium,Transcription factor,FOXA1 mutations can drive resistance to hormonal therapy.,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8616385/
Prostate,Taxane,TLE3,TLE3,Expression loss,Non-response,"IHC, RNA-seq",Medium,Transcriptional corepressor,Loss of TLE3 associated with poor taxane response,"TCGA, GEO",https://www.carislifesciences.com/research/publications/taxane-sensitivity-markers-in-prostate-cancer/
Prostate,Taxane,TMPRSS2–ERG fusion,"TMPRSS2, ERG",Genomic rearrangement,Response,"FISH, PCR, NGS",Medium,Transcription factor,Fusion-positive tumors show better response to taxanes,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC11564108/
Prostate,Taxane,MAPT (Tau),MAPT,Overexpression,Non-response,"IHC, RNA-seq",Medium,Microtubule-associated protein,High tau expression confers resistance by stabilizing microtubules,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC7259995/
Prostate,Taxane,BCL2,BCL2,Overexpression,Non-response,"IHC, RNA-seq",Medium,Anti-apoptotic protein,"High BCL2 inhibits apoptosis, reducing taxane efficacy","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7259995/
Prostate,Taxane,AKT1,AKT1,Amplification,Non-response,"RNA-seq, PCR",Medium,Kinase,"AKT1 activation promotes survival, reducing taxane sensitivity","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7259995/
Prostate,Taxane,BRCA2,BRCA2,"Mutation, Deletion",Response,"NGS, PCR",Medium,DNA repair protein,BRCA2 loss may sensitize to taxanes via impaired DNA repair,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7259995/
Skin Melanoma,Anti-PD-1,B2M,B2M,"Mutation, Deletion",Non-response,Somatic mutation analysis,Medium,MHC class I component,"Loss impairs antigen presentation, leading to immune escape","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/
Skin Melanoma,Anti-PD-1,JAK1,JAK1,"Mutation, Disruption",Non-response,Somatic mutation analysis,Medium,Tyrosine kinase,"Mutations disrupt IFN-γ signaling, reducing immune response","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/
Skin Melanoma,Anti-PD-1,JAK2,JAK2,"Mutation, Disruption",Non-response,Somatic mutation analysis,Medium,Tyrosine kinase,"Similar to JAK1, disrupts IFN-γ pathway","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/
Skin Melanoma,Anti-PD-1,PTEN,PTEN,"Deletion, Mutation",Non-response,Somatic mutation analysis,Medium,Phosphatase,Loss leads to immune resistance via PI3K/AKT pathway activation,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/
Skin Melanoma,Anti-PD-1,NRAS,NRAS,Mutation,Non-response,Somatic mutation analysis,Medium,GTPase,"Activates MAPK pathway, associated with resistance","TCGA, COSMIC",https://jitc.bmj.com/content/10/7/e004879
Skin Melanoma,Anti-PD-1,WNT/β-catenin Pathway,CTNNB1,"Mutation, Activation",Non-response,"RNA-seq, mutation analysis",Medium,Transcription co-activator,"Activation excludes T cell infiltration, leading to resistance","TCGA, COSMIC",https://jitc.bmj.com/content/10/7/e004879
Skin Melanoma,Anti-PD-1,IFN-γ Signature,Multiple,Expression,Response,RNA-seq,Medium,Cytokine,Indicates active immune microenvironment,"TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/, https://jitc.bmj.com/content/10/7/e004879"
Skin Melanoma,Anti-PD-1,LAG-3,LAG3,Expression,Non-response,"IHC, RNA-seq",Medium,Immune checkpoint,"Co-inhibitory receptor, upregulation linked to resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/
Skin Melanoma,Anti-PD-1,TIM-3,HAVCR2,Expression,Non-response,"IHC, RNA-seq",Medium,Immune checkpoint,Upregulation associated with T cell exhaustion and resistance,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/
Skin Melanoma,Anti-PD-1,MHC Class I,HLA-A/B/C,"Deletion, Downregulation",Non-response,"IHC, RNA-seq",Medium,Antigen-presenting,"Loss impairs antigen presentation, leading to immune escape","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/
Skin Melanoma,Anti-PD-1,T cell inflamed gene expression profile (Tcell infGEP),Multiple,Expression,Response,RNA-seq,Medium,Multiple,Reflects immune-active tumor microenvironment,"TCGA, GEO",https://jitc.bmj.com/content/10/7/e004879
Skin Melanoma,Immunotherapy,PD-1,PDCD1,Expression,Response,"IHC, RNA-seq",Medium,Immune checkpoint receptor,Marker of T-cell exhaustion; high levels on TILs linked to response,"TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC8070445/, https://www.curemelanoma.org/blog/how-biomarkers-are-used-in-melanoma"
Skin Melanoma,Immunotherapy,CTLA-4,CTLA4,Expression,Response,"IHC, RNA-seq",Medium,Immune checkpoint receptor,Regulates T-cell activation; target of ipilimumab,"TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC8070445/, https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/"
Skin Melanoma,Immunotherapy,TERT Promoter,TERT,Mutation,Non-response,"PCR, NGS",Medium,Reverse transcriptase,Associated with poor prognosis and resistance to immunotherapy,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/
Skin Melanoma,Immunotherapy,LAG-3,LAG3,Expression,Non-response,"IHC, RNA-seq",Medium,Immune checkpoint receptor,Marker of T-cell exhaustion; high expression linked to resistance,"TCGA, GEO",https://www.mdpi.com/1422-0067/24/1/41
Skin Melanoma,Immunotherapy,MDSCs (CD14+),CD14,Expansion,Non-response,Flow cytometry,Medium,Surface glycoprotein,"Suppress T-cell function, associated with poor response","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/
Skin Melanoma,Immunotherapy,FOXP3+ Tregs,FOXP3,Infiltration,Non-response,"IHC, Flow cytometry",Medium,Transcription factor,Regulatory T cells suppress anti-tumor immunity,"TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC8070445/, https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/"
Skin Melanoma,Immunotherapy,Beta-2-microglobulin,B2M,Mutation/Deletion,Non-response,"NGS, PCR",Medium,MHC class I component,"Loss impairs antigen presentation, leading to immune escape","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC8070445/
Skin Melanoma,Immunotherapy,IFN-γ Signature,IFNG,Expression,Response,"RNA-seq, qPCR",Medium,Cytokine,Indicates active anti-tumor immune response,"TCGA, GEO","https://pmc.ncbi.nlm.nih.gov/articles/PMC8070445/, https://www.mdpi.com/1422-0067/24/1/41"
Unknown primary (e.g. CUP),Chemotherapy,CDKN2A,CDKN2A,Deletion,Non-response,"NGS, FISH",Medium,Tumor suppressor,"Loss promotes cell cycle progression, linked to poor response","TCGA, COSMIC",https://ascopubs.org/doi/10.1200/OA-24-00041
Unknown primary (e.g. CUP),Chemotherapy,PIK3CA,PIK3CA,Mutation,Non-response,"NGS, PCR",Medium,Enzyme (kinase),"Activates PI3K/AKT pathway, associated with resistance to therapy","TCGA, COSMIC",https://ascopubs.org/doi/10.1200/OA-24-00041
Unknown primary (e.g. CUP),Chemotherapy,ALK,ALK,Rearrangement,Response,"FISH, NGS",Medium,Receptor tyrosine kinase,ALK fusions predict response to ALK inhibitors,"TCGA, COSMIC",https://ascopubs.org/doi/10.1200/OA-24-00041
Unknown primary (e.g. CUP),Chemotherapy,IDH1,IDH1,Mutation,Non-response,"NGS, PCR",Medium,Enzyme,Mutations linked to resistance in some contexts,"TCGA, COSMIC",https://ascopubs.org/doi/10.1200/OA-24-00041
Unknown primary (e.g. CUP),Chemotherapy,FGFR2,FGFR2,Amplification,Response,"FISH, NGS",Medium,Receptor tyrosine kinase,FGFR2 alterations predict response to FGFR inhibitors,"TCGA, COSMIC",https://ascopubs.org/doi/10.1200/OA-24-00041
Unknown primary (e.g. CUP),Chemotherapy,EGFR,EGFR,Mutation,Response,"NGS, PCR",Medium,Receptor tyrosine kinase,EGFR mutations predict response to EGFR inhibitors,"TCGA, COSMIC",https://ascopubs.org/doi/10.1200/OA-24-00041
Bladder Urothelial,Anti-PD-1,LAG-3,LAG3,Expression,Non-response,"IHC, RNA-seq",Low,Immune checkpoint receptor,"Marker of T-cell exhaustion, associated with resistance","TCGA, COSMIC",https://jitc.bmj.com/content/5/1/94
Bladder Urothelial,Anti-PD-1,TIM-3,HAVCR2,Expression,Non-response,"IHC, RNA-seq",Low,Immune checkpoint receptor,"T-cell exhaustion marker, linked to resistance","TCGA, COSMIC",https://jitc.bmj.com/content/5/1/94
Bladder Urothelial,Anti-PD-1,CTLA-4,CTLA4,Expression,Non-response,"IHC, RNA-seq",Low,Immune checkpoint receptor,Negative regulator of T-cell activation,"TCGA, COSMIC",https://jitc.bmj.com/content/5/1/94
Bladder Urothelial,Anti-PD-1,STK11/LKB1 Mutation,STK11,Mutation,Non-response,"NGS, PCR",Low,Kinase,"Tumor suppressor, loss linked to immune evasion","TCGA, COSMIC",https://jitc.bmj.com/content/5/1/94
Bladder Urothelial,Anti-PD-1,C-reactive protein (CRP),CRP,Expression,Non-response,"ELISA, blood test",Low,Acute phase protein,"High levels linked to systemic inflammation, poor response",GEO,https://pmc.ncbi.nlm.nih.gov/articles/PMC10486227/
Bladder Urothelial,Immunotherapy,LAG3,LAG3,Expression,Non-response,"IHC, RNA-seq",Low,Immune checkpoint,"High expression may indicate T-cell exhaustion, reduced ICI efficacy","TCGA, GEO",https://jitc.bmj.com/content/5/1/94
Bladder Urothelial,Immunotherapy,CDKN2A deletion,CDKN2A,Deletion,Non-response,"NGS, PCR",Low,Tumor suppressor,Loss associated with immune evasion and poor ICI response,"TCGA, COSMIC",https://jitc.bmj.com/content/5/1/94
Bladder Urothelial,Immunotherapy,Circulating tumor DNA (ctDNA),Multiple,Somatic Mutations,Response/Non-response,"Liquid biopsy, NGS",Low,N/A (Genomic feature),ctDNA dynamics may reflect tumor burden and response to immunotherapy,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10486227/
Breast ER+/HER-,Aromatase inhibitor,S6K1 Amplification,RPS6KB1,Amplification,Non-response,"FISH, PCR",Low,Kinase,"Activates mTOR pathway, linked to resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Chemotherapy,FOXA1,FOXA1,Mutation,Response,Somatic mutation analysis,Low,Transcription factor,"Regulates ER function, mutations may affect response","TCGA, COSMIC",https://ascopubs.org/doi/10.1200/JCO.22.00069
Breast ER+/HER-,Chemotherapy,MDM2 Amplification,MDM2,Amplification,Non-response,"FISH, PCR",Low,E3 ubiquitin ligase,"Inhibits p53, amplification linked to resistance","TCGA, COSMIC",https://ascopubs.org/doi/10.1200/JCO.22.00069
Breast ER+/HER-,Hormonal therapy,AR (Androgen Receptor),AR,Expression,Response/Non-response,"IHC, RNA-seq",Low,Nuclear receptor,May modulate ER signaling; role in response is context-dependent,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Hormonal therapy,MDM2,MDM2,Amplification,Non-response,"FISH, NGS",Low,E3 ubiquitin ligase,"Amplification can inhibit p53, contributing to resistance","TCGA, COSMIC",https://www.jcancer.org/v07p1281.htm
Breast ER+/HER-,Hormonal therapy,AR (Androgen R.),AR,Expression,Response,"IHC, RNA-seq",Low,Nuclear receptor,Expression may predict response in some ER+ tumors,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Breast ER+/HER-,Hormonal therapy,MDM2,MDM2,Amplification,Non-response,"FISH, PCR",Low,E3 ubiquitin ligase,Amplification may drive resistance via p53 pathway,"TCGA, COSMIC",https://www.jcancer.org/v07p1281.htm
Breast Triple Negative,Chemotherapy,AR,AR,Overexpression,Non-response,"IHC, PCR",Low,Nuclear receptor,Androgen receptor expression linked to chemo resistance in some TNBC subtypes,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC4675910/
Breast Triple Negative,Chemotherapy,C-kit,KIT,Overexpression,Non-response,"IHC, PCR",Low,Receptor tyrosine kinase,Overexpression associated with poor prognosis and chemo resistance,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC4675910/
Colon,Chemotherapy,APC,APC,Mutation,Non-response,"Somatic mutation (PCR, NGS)",Low,Tumor suppressor,Loss of function may affect chemotherapy response,"TCGA, COSMIC",https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,SMAD4,SMAD4,Mutation/Deletion,Non-response,"Somatic mutation (PCR, NGS)",Low,Transcription factor,Loss linked to poor prognosis and therapy resistance,"TCGA, COSMIC",https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,TGFBR2 mutation,TGFBR2,Mutation,Non-response,"PCR, NGS",Low,Receptor kinase,"Disrupts TGF-beta signaling, associated with chemoresistance","TCGA, COSMIC",https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,SMAD4 mutation,SMAD4,Mutation,Non-response,"PCR, NGS",Low,Transcription factor,"Disrupts TGF-beta signaling, linked to chemoresistance","TCGA, COSMIC",https://www.mdpi.com/2072-6694/16/16/2796
Colon,Chemotherapy,ERCC1 expression,ERCC1,Overexpression,Non-response,"IHC, qPCR",Low,DNA repair enzyme,High expression linked to resistance to platinum-based chemotherapy,"TCGA, GEO",https://www.mdpi.com/2072-6694/16/16/2796
Gastroesophageal,Chemotherapy,Topoisomerase I,TOP1,Overexpression,Response,"IHC, qPCR",Low,Enzyme,High TOP1 expression may predict response to irinotecan[2].,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10380533/
Gastroesophageal,Chemotherapy,NTRK Fusions,NTRK1/2/3,Fusion,Response,"NGS, FISH",Low,Receptor tyrosine kinase,NTRK fusions predict response to TRK inhibitors[1].,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7530320/
Gastroesophageal,Chemotherapy,RRM1,RRM1,Overexpression,Non-response,"IHC, qPCR",Low,Enzyme,High RRM1 expression linked to resistance to gemcitabine[2].,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10380533/
Kidney,Multikinase inhibitor,SETD2,SETD2,Mutation,Non-response,Somatic mutation analysis (NGS),Low,Histone methyltransferase,Loss linked to poor prognosis and resistance to therapy,"TCGA, COSMIC",https://ascopubs.org/doi/10.1200/EDBK_430734
Kidney,Multikinase inhibitor,TERT,TERT,Promoter Mutation,Non-response,"PCR, NGS",Low,Reverse transcriptase,TERT promoter mutations associated with aggressive disease and poor response,"TCGA, COSMIC",https://ascopubs.org/doi/10.1200/EDBK_430734
Kidney,Multikinase inhibitor,TMB (Tumor Mutation Burden),Various,Mutation,Response,"NGS, WES",Low,N/A (aggregate),"High TMB may predict response to immunotherapy, less clear for TKIs","TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC8566366/, https://ascopubs.org/doi/10.1200/EDBK_430734"
Kidney,Targeted therapy,TERT,TERT,Promoter mutation,Non-response,"PCR, NGS",Low,Enzyme (telomerase),"Promoter mutations linked to aggressive disease, poor response","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10645469/
Kidney,Targeted therapy,miR-210,MIR210,Overexpression,Response/Non-response,"qRT-PCR, RNA-seq",Low,microRNA,"Hypoxia marker, may modulate therapy response",GEO,https://pmc.ncbi.nlm.nih.gov/articles/PMC10645469/
Kidney,Targeted therapy,miR-21,MIR21,Overexpression,Non-response,"qRT-PCR, RNA-seq",Low,microRNA,Associated with resistance to targeted therapies,GEO,https://pmc.ncbi.nlm.nih.gov/articles/PMC10645469/
Kidney,Targeted therapy,FLCN,FLCN,Mutation,Response,"NGS, PCR",Low,Tumor suppressor,Mutations linked to response to mTOR inhibitors,"TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC10645469/
Lung NSCLC,Anti-PD-1,Microbiome Signature,N/A,N/A,Response,16S rRNA sequencing,Low,N/A,Certain gut microbiota compositions linked to better response,GEO,https://www.cancernetwork.com/view/print-biomarkers-for-response-to-anti-pd-1-anti-pd-l1-immune-checkpoint-inhibitors-a-large-meta-analysis
Lung NSCLC,Anti-PD-1,LAG-3 Expression,LAG3,Expression,Non-response,"IHC, Flow cytometry",Low,Immune checkpoint receptor,High expression may indicate T-cell exhaustion and resistance,"TCGA, GEO",https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1157100/full
Lung NSCLC,Anti-PD-1,TIM-3 Expression,HAVCR2,Expression,Non-response,"IHC, Flow cytometry",Low,Immune checkpoint receptor,High expression associated with immune escape and resistance,"TCGA, GEO",https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1157100/full
Lung NSCLC,Chemotherapy,TUBB4,TUBB4,Expression,Non-response,"IHC, PCR",Low,Structural protein,High TUBB4 expression may predict taxane resistance,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC6025105/
Lung NSCLC,Chemotherapy,BCL2,BCL2,Expression,Non-response,"IHC, PCR",Low,Apoptosis regulator,High BCL2 expression may confer resistance to chemotherapy,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC6025105/
Lung NSCLC,Immunotherapy,LAMC3 Mutation,LAMC3,Mutation,Non-response,NGS,Low,Extracellular matrix,May affect tumor microenvironment and immune evasion,TCGA,https://pcm.amegroups.org/article/view/7603/html
Ovary,Chemotherapy,PIK3CA,PIK3CA,Mutation,Non-response,"NGS, PCR",Low,Kinase,Activating mutations linked to chemoresistance in some cohorts,"TCGA, COSMIC",https://erc.bioscientifica.com/view/journals/erc/25/5/ERC-17-0336.xml
Ovary,Chemotherapy,BCL2,BCL2,Overexpression,Non-response,"IHC, qPCR",Low,Apoptosis regulator,"Overexpression inhibits apoptosis, leading to chemoresistance","TCGA, GEO",https://erc.bioscientifica.com/view/journals/erc/25/5/ERC-17-0336.xml
Ovary,Chemotherapy,AKT2,AKT2,Amplification,Non-response,"qPCR, IHC",Low,Kinase,Amplification linked to poor prognosis and chemoresistance,"TCGA, COSMIC",https://erc.bioscientifica.com/view/journals/erc/25/5/ERC-17-0336.xml
Pan-Cancer,Alkaloid,Ki-67,MKI67,Amplification,Response,"IHC, RNA-seq",Low,Proliferation marker,High proliferation index predicts better response to cell cycle-targeting alkaloids,"TCGA, GEO",https://pubs.rsc.org/en/content/articlehtml/2025/ra/d4ra05089d
Pan-Cancer,Alkylating,LINGO1,LINGO1,Expression,Response,"RNA-seq, IHC",Low,Transmembrane protein,High expression identifies subpopulations with increased response to alkylating agents.,TCGA,https://pmc.ncbi.nlm.nih.gov/articles/PMC11384948/
Pan-Cancer,Alkylating,FOXP1,FOXP1,Downregulation,Response,"RNA-seq, IHC",Low,Transcription factor,"Suppressed by miR-181a, contributing to increased sensitivity.",TCGA,https://pmc.ncbi.nlm.nih.gov/articles/PMC9019174/
Pan-Cancer,Alkylating,BCL2L11,BCL2L11,Downregulation,Non-response,"RNA-seq, IHC",Low,Apoptosis regulator,"Targeted by miR-93, leading to reduced apoptosis and resistance.",TCGA,https://pmc.ncbi.nlm.nih.gov/articles/PMC9019174/
Pan-Cancer,Alkylating,p21,CDKN1A,Downregulation,Non-response,"RNA-seq, IHC",Low,Cell cycle regulator,"Targeted by miR-93, reducing cell cycle arrest and promoting resistance.",TCGA,https://pmc.ncbi.nlm.nih.gov/articles/PMC9019174/
Pan-Cancer,Alkylating,p27,CDKN1B,Downregulation,Non-response,"RNA-seq, IHC",Low,Cell cycle regulator,"Targeted by miR-221/222, reducing cell cycle arrest and promoting resistance.",TCGA,https://pmc.ncbi.nlm.nih.gov/articles/PMC9019174/
Pan-Cancer,Anti-AR,CHD1 Deletion,CHD1,Deletion,Response,"WES, FISH",Low,Chromatin remodeler,Loss sensitizes tumors to AR-targeted therapy,"TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/22/5723
Pan-Cancer,Anti-CTLA-4,NK Cell Subsets,NCR1,N/A,Non-response,"CyTOF, Flow cytometry",Low,Immune cell marker,Dysfunctional NK cells linked to poor response,"GEO, TCGA","https://pmc.ncbi.nlm.nih.gov/articles/PMC5840795/, https://pubmed.ncbi.nlm.nih.gov/29510697/"
Pan-Cancer,Anti-EGFR,EGFR S492R,EGFR,Mutation,Non-response,"Somatic mutation (NGS, PCR)",Low,Receptor tyrosine kinase,"Alters antibody binding, confers resistance",COSMIC,https://pmc.ncbi.nlm.nih.gov/articles/PMC2758310/
Pan-Cancer,Anti-EGFR,TP53 mutation,TP53,Mutation,Non-response,"Somatic mutation (NGS, PCR)",Low,Transcription factor,"May affect apoptosis and cell cycle, linked to resistance","TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Anti-EGFR,SMAD4 mutation,SMAD4,Mutation,Non-response,"Somatic mutation (NGS, PCR)",Low,Signal transducer,"Loss impairs TGF-β signaling, associated with resistance","TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Anti-EGFR,FBXW7 mutation,FBXW7,Mutation,Non-response,"Somatic mutation (NGS, PCR)",Low,Ubiquitin ligase,"Alters degradation of oncoproteins, linked to resistance","TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Anti-EGFR,miR-31 expression,MIR31,Overexpression,Non-response,"miRNA profiling (qPCR, NGS)",Low,microRNA,"Regulates gene expression, high levels linked to poor response",GEO,https://pmc.ncbi.nlm.nih.gov/articles/PMC4974592/
Pan-Cancer,Anti-PD-1,Germline miRNA Signature,Multiple,Germline Variation,Non-response (toxicity),miRNA sequencing,Low,N/A (Regulatory RNA),"Predicts immune-related adverse events, not directly linked to response","TCGA, GEO",https://jitc.bmj.com/content/10/2/e003625
Pan-Cancer,Aromatase inhibitor,"Immune Markers (e.g., PD-L1)",CD274,Overexpression,Non-response,"IHC, RNA-seq",Low,Immune checkpoint,High immune infiltration/PD-L1 linked to poor AI response in some subtypes,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10328947/
Pan-Cancer,Chemotherapy,BLM,BLM,Mutation,Response,"NGS, PCR",Low,DNA helicase,Mutations may increase sensitivity to DNA-damaging agents,"TCGA, COSMIC","https://pmc.ncbi.nlm.nih.gov/articles/PMC10073273/, https://www.binasss.sa.cr/set21/46.pdf"
Pan-Cancer,Hormonal therapy,GATA3,GATA3,Mutation,Response,"NGS, RNA-seq",Low,Transcription factor,"Maintains luminal phenotype, associated with better response","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Hormonal therapy,MDM2 Amplification,MDM2,Amplification,Non-response,"FISH, NGS",Low,E3 ubiquitin ligase,"Inhibits p53, associated with resistance","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC7922594/
Pan-Cancer,Multikinase inhibitor,NFE2L2 Expression,NFE2L2,Overexpression,Non-response,"RNA-seq, IHC",Low,Transcription factor,Regulates oxidative stress; associated with immune infiltration and resistance,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC9169228/
Pan-Cancer,Multikinase inhibitor,PINK1 Downregulation,PINK1,Downregulation,Non-response,"RNA-seq, IHC",Low,Kinase (enzyme),Mitochondrial quality control; downregulation may reduce therapy sensitivity,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC9169228/
Pan-Cancer,Platinum,XRCC1,XRCC1,"Mutation, SNP",Non-response,"SNP genotyping, NGS",Low,DNA repair enzyme,Base excision repair; certain variants linked to reduced platinum sensitivity,"TCGA, COSMIC",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Platinum,BCL2,BCL2,"Amplification, Overexpression",Non-response,"IHC, RNA-seq, qPCR",Low,Anti-apoptotic protein,"Overexpression inhibits apoptosis, conferring resistance to platinum","TCGA, GEO",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Platinum,ABCC2 (MRP2),ABCC2,"Amplification, Overexpression",Non-response,"IHC, RNA-seq, qPCR",Low,Drug transporter,"Effluxes platinum drugs, reducing intracellular concentration","TCGA, GEO",https://www.binasss.sa.cr/set21/46.pdf
Pan-Cancer,Pyrimidine (ant)agonist,Uridine Phosphorylase,UPP1,Overexpression,Response,"RNA-seq, IHC",Low,Enzyme,Converts 5-FU to active metabolites; higher expression linked to better response,TCGA,https://research.rug.nl/files/2914175/thesis.pdf
Pan-Cancer,Pyrimidine (ant)agonist,"CAD (Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, dihydroorotase)",CAD,"Phosphorylation, Overexpression",Non-response,"RNA-seq, IHC, Phospho-proteomics",Low,Multifunctional enzyme,Controls pyrimidine synthesis; MAPK-mediated phosphorylation increases resistance,TCGA,https://pmc.ncbi.nlm.nih.gov/articles/PMC8194085/
Pan-Cancer,Pyrimidine (ant)agonist,Uridine Kinase,UCK1/2,Overexpression,Response,"RNA-seq, IHC",Low,Enzyme,"Phosphorylates uridine analogs, activating prodrugs",TCGA,https://research.rug.nl/files/2914175/thesis.pdf
Pan-Cancer,Pyrimidine (ant)agonist,Thymidine Kinase,TK1,Overexpression,Response,"RNA-seq, IHC",Low,Enzyme,"Phosphorylates thymidine analogs, activating prodrugs",TCGA,https://research.rug.nl/files/2914175/thesis.pdf
Pan-Cancer,Pyrimidine (ant)agonist,ZEB1,ZEB1,Overexpression,Non-response,"RNA-seq, IHC",Low,Transcription factor,"EMT driver; upregulated by TS, associated with resistance and metastasis",TCGA,https://pmc.ncbi.nlm.nih.gov/articles/PMC8194085/
Pancreas PAAD,Chemotherapy,Exosome DNA,Various,High exoDNA levels,Non-response,"Liquid biopsy, NGS",Low,N/A (DNA),High exoDNA predicts poor survival/response,"TCGA, GEO",https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.866173/full
Pancreas PAAD,Chemotherapy,CXCL12,CXCL12,Overexpression,Non-response,"RNA-seq, IHC",Low,Chemokine,High levels linked to immune exclusion and poor response,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC10293428/
Pancreas PAAD,Folinic acid,SPARC,SPARC,Expression,Response,"IHC, RNA-seq",Low,Glycoprotein,High expression may predict response to albumin-bound drugs,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC6478006/
Pancreas PAAD,Folinic acid,MMR Deficiency,"MLH1, etc.",Mutation/Loss,Response,"IHC, PCR",Low,DNA repair enzyme,"Deficiency may predict response to immunotherapy, less clear for FOLFIRINOX","TCGA, COSMIC",https://pmc.ncbi.nlm.nih.gov/articles/PMC6478006/
Prostate,Anti-AR,CHD1 Loss,CHD1,Deletion,Response,"NGS, FISH",Low,Chromatin remodeler,Loss may sensitize to AR-targeted therapy,"TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/22/5723
Prostate,Anti-AR,FOXA1 Mutation,FOXA1,Mutation,Non-response,"NGS, Sanger sequencing",Low,Transcription factor,"Alters AR cistrome, potentially driving resistance","TCGA, COSMIC",https://www.mdpi.com/2072-6694/13/22/5723
Prostate,Chemotherapy,L-selectin,SELL,Overexpression,Non-response,"ELISA, IHC",Low,Cell adhesion molecule,Linked to immune evasion and poor prognosis,"GEO, TCGA",https://journals.sagepub.com/doi/10.1177/15330338241290029
Prostate,Chemotherapy,Ceruloplasmin,CP,Overexpression,Non-response,"ELISA, IHC",Low,Enzyme,"Oxidative stress marker, associated with aggressive disease","GEO, TCGA",https://journals.sagepub.com/doi/10.1177/15330338241290029
Prostate,Chemotherapy,GOAT,MBOAT4,Overexpression,Non-response,"ELISA, IHC",Low,Enzyme,"Modifies ghrelin, promoting tumor growth and therapy resistance","GEO, TCGA",https://journals.sagepub.com/doi/10.1177/15330338241290029
Prostate,Hormonal therapy,CYP17A1 Expression,CYP17A1,Overexpression,Non-response,"IHC, qPCR",Low,Enzyme,High CYP17A1 may confer resistance to abiraterone.,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC8616385/
Prostate,Hormonal therapy,AKR1C3 Expression,AKR1C3,Overexpression,Non-response,"IHC, qPCR",Low,Enzyme,AKR1C3 upregulation linked to resistance to androgen synthesis inhibitors.,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC8616385/
Prostate,Taxane,CYP1B1,CYP1B1,Overexpression,Non-response,"RNA-seq, PCR",Low,Enzyme,"CYP1B1 metabolizes taxanes, reducing efficacy","TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC7259995/
Prostate,Taxane,NEK2,NEK2,Overexpression,Non-response,"RNA-seq, PCR",Low,Kinase,NEK2 overexpression linked to mitotic defects and taxane resistance,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC7259995/
Skin Melanoma,Anti-PD-1,CD11c+ Dendritic Cells,ITGAX,Expression,Response,"IHC, RNA-seq",Low,Immune cell marker,Increased density linked to better response,"TCGA, GEO",https://jitc.bmj.com/content/10/7/e004879
Skin Melanoma,Immunotherapy,HLA-A*26,HLA-A,Polymorphism,Response,Genotyping,Low,MHC class I molecule,Influences antigen presentation and immune recognition,"TCGA, GEO",https://pmc.ncbi.nlm.nih.gov/articles/PMC6058029/
Skin Melanoma,Immunotherapy,IL-17,IL17A,Expression,Non-response,"ELISA, RNA-seq",Low,Cytokine,"Promotes inflammation, may contribute to resistance","TCGA, GEO",https://www.mdpi.com/1422-0067/24/1/41
Breast ER+/HER-,Chemotherapy,"","","","","",,"","","",""
